U.S. patent application number 13/341843 was filed with the patent office on 2012-05-24 for barriers for facilitating biological reactions.
This patent application is currently assigned to NORTHWESTERN UNIVERSITY. Invention is credited to David M. Kelso, Zaheer Parpia, Kunal Sur.
Application Number | 20120129156 13/341843 |
Document ID | / |
Family ID | 41056566 |
Filed Date | 2012-05-24 |
United States Patent
Application |
20120129156 |
Kind Code |
A1 |
Kelso; David M. ; et
al. |
May 24, 2012 |
BARRIERS FOR FACILITATING BIOLOGICAL REACTIONS
Abstract
The present invention relates to systems, devices, and methods
for performing biological reactions. In particular, the present
invention relates to the use of lipophilic, water immiscible, or
hydrophobic barriers in sample separation, purification,
modification, and analysis processes.
Inventors: |
Kelso; David M.; (Wilmette,
IL) ; Sur; Kunal; (Evanston, IL) ; Parpia;
Zaheer; (Evanston, IL) |
Assignee: |
NORTHWESTERN UNIVERSITY
EVANSTON
IL
|
Family ID: |
41056566 |
Appl. No.: |
13/341843 |
Filed: |
December 30, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12395020 |
Feb 27, 2009 |
|
|
|
13341843 |
|
|
|
|
61032655 |
Feb 29, 2008 |
|
|
|
Current U.S.
Class: |
435/5 ; 422/527;
435/6.12; 436/177 |
Current CPC
Class: |
G01N 33/54393 20130101;
B01L 7/52 20130101; B01L 2300/087 20130101; B01L 3/502761 20130101;
G01N 33/54366 20130101; B01L 2200/10 20130101; B01L 2200/0647
20130101; B01L 2400/0677 20130101; B01L 2200/16 20130101; B01L
2400/043 20130101; B01L 2200/04 20130101; Y10T 436/25375 20150115;
B01L 3/50851 20130101 |
Class at
Publication: |
435/5 ; 422/527;
436/177; 435/6.12 |
International
Class: |
G01N 1/28 20060101
G01N001/28; C12Q 1/68 20060101 C12Q001/68; C12Q 1/70 20060101
C12Q001/70; B01L 99/00 20100101 B01L099/00 |
Goverment Interests
GOVERNMENT SUPPORT
[0002] This invention was made with government support under Grant
No CCF0329957 awarded by the National Science Foundation and Grant
No. 5R01EB001418-03 awarded by the National Institutes of Health.
The government has certain rights in the invention.
Claims
1. A device for facilitating extraction of a biological sample, the
biological sample including non-desired material and a biological
molecule of interest bound to a solid phase, the device comprising:
a first chamber for receiving the biological sample therein; a
region for receiving a lipophilic material therein; a second
chamber for receiving a reagent therein; and a transport mechanism
moveable between a first position adjacent the first chamber and a
second position adjacent the second chamber; wherein the mechanism
urges the molecule of interest bound solid phase from the first
chamber, through the region and into the second chamber.
2. The device of claim wherein the lipophilic material is an oil,
the oil preventing the non-desired material from passing
therethrough.
3. The device of claim 1 further comprising a first channel having
an input in communication with the first chamber and an output in
communication with the region.
4. The device of claim 3 further comprising a second channel having
an input in communication with the region and an output in
communication with the second chamber.
5. The device of claim 1 further comprising a plate having an upper
surface, the upper surface including: a first hydrophilic portion
communicating with the biological sample; a second hydrophilic
portion communicating with the reagent; and a hydrophobic portion
communicating with the lipophilic material.
6. A device for facilitating extraction of a biological molecule of
interest from a biological sample, the biological sample including
non-desired material and the biological molecule of interest bound
to a solid phase, the device comprising: a first chamber for
receiving the biological sample therein; a second chamber for
receiving a reagent therein; a pathway interconnecting the first
chamber and the second chamber, and a transport mechanism movable
between a first position adjacent the first chamber and a second
position adjacent the second chamber; wherein the transport
mechanism urges the molecule of interest bound solid phase from the
first chamber, through the pathway and into the second chamber.
7. The device of claim 6 further comprising a lipophilic material
disposed in the pathway, the lipophilic material preventing the
non-desired material from passing therethrough.
8. The device of claim 7 wherein the pathway includes a region for
housing the lipophilic material.
9. The device of claim 8 wherein the pathway is at least partially
defined by a first channel having an input in communication with
the first chamber and an output communicating with the region.
10. The device of claim 9 wherein the pathway is further defined by
a second channel having an input in communication with the region
and an output communicating with the second chamber.
11. The device of claim 6 further comprising a plate having an
upper surface, the upper surface including: a first hydrophilic
portion communicating with the biological sample; a second
hydrophilic portion communicating with the reagent; and a
hydrophobic portion partially defining the pathway.
12. A method for facilitating extraction of a fraction from a
biological sample, the biological sample including non-desired
material and a biological molecule of interest bound to a solid
phase, the method comprising the steps of: depositing the
biological sample in a first chamber; and drawing the biological
molecule bound phase substrate from the first chamber, through an
intermediate region and into the second chamber with a force.
13. The method of claim 12 wherein the intermediate region includes
a lipophilic material preventing the non-desired material from
passing therethrough.
14. The method of claim 13 wherein the lipophilic material is an
oil.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 12/395,020 filed Feb. 27, 2009, now pending, which claims
priority to U.S. Provisional Patent Application Ser. No.
61/032,655, filed Feb. 29, 2008, each of which are herein
incorporated by reference in their entirety.
FIELD OF THE INVENTION
[0003] The present invention relates to systems, devices, and
methods for performing biological reactions. In particular, the
present invention relates to the use of hydrophobic,
water-immiscible, or lipophilic barriers in sample separation,
purification, modification, and analysis processes.
BACKGROUND OF THE INVENTION
[0004] There is a great need for cost-effective, easy to use
systems, methods, and devices for analyzing biological samples.
Many commercially available systems cost tens to hundreds of
thousands of dollars and have many moving parts which make them
prone to failure. Because of the cost and complexity of such
systems, their use has generally been limited to clinical
laboratories which have the personnel and services needed to
support their operation and maintenance.
[0005] One class of fully integrated automated analyzers,
represented by the Abbott Architect, Siemens Centaur, Roche
Elecsys, and others, perform immunoassays. Another class of modular
analyzers, represented by the Abbott m2000, Roche COBAS, bioMerieux
NucliSENS and others, perform nucleic acid assays. Much of the
complexity of these systems is a result of separation steps
involved in processing the assays.
[0006] Modular systems are also frequently used in research
laboratories. Immunoassay separations may be performed by plate
washers such as Titertek MAP-C2, BioTek ELx50, Tecan PW 96/384 and
others. Nucleic acid separations are performed by systems such as
the Applied Biosystems PRISM.TM. 6100, Invitrogen iPrep, Thermo
Scientific KingFisher, Promega Maxwell, and others.
[0007] The availability of low-cost, reliable analyzers is of
particular concern as it relates to the diagnosis and management of
disease around the world. This problem is vividly illustrated by
the problems associated with management of HIV infections. Many
technologies exist that permit detection of nucleic acids or
protein levels associated with HIV. This detection is important for
managing the patient care of those infected by HIV. However, the
cost and complexity of these systems prohibits their widespread
use.
SUMMARY OF THE INVENTION
[0008] The present invention relates to systems, devices, and
methods for performing biological reactions. In particular, the
present invention relates to the use of hydrophobic, water or
alcohol-immiscible, or lipophilic barriers in sample separation,
purification, modification, and analysis processes.
[0009] In some embodiments, the present invention provides a
biological sample purification and/or analysis device, comprising:
a plurality of sample processing chambers comprising reagents for
biological molecule or cell purification, modification, analysis,
and/or detection; and a lipophilic substance in between (e.g.,
separating) two or more of the chambers. In some embodiments, the
lipophilic substance is a wax. In some embodiments, the wax is a
phase change wax that can take liquid or solid forms of
pre-determined temperatures. For example, in some embodiments, the
wax takes solid form at storing or shipping temperatures and liquid
form at reaction temperature (e.g., room temperature). In some
embodiments, the lipophilic substance is an oil. In some
embodiments, there are two reaction chambers. In some embodiments,
there are three reaction chambers. In some embodiments, there are
four reaction chambers. In some embodiments, there are five
reactions chambers. In some embodiments, there are six or more
reaction chambers (e.g., 7, 8, 9, 10, 11, . . ., 20, . . .). In
some embodiments, the lipophilic material provides a contiguous
barrier between two or more of the chambers (i.e., a sample passes
from a first chamber directly into the lipophilic material and
directly out of the lipophilic material into the second chamber).
In other embodiments, there is air, liquid, or other material
between the lipophilic material and one or more of the chambers. In
such embodiments, the lipophilic material is positioned such that a
sample or biological molecule to be processed passes through the
lipophilic material at some point between its transit from a first
chamber to a second chamber.
[0010] In some embodiments, all of, or a subset of the reaction
chambers are dedicated for sample purification. For example, one or
more reaction chambers contain reagents that cause a sample
purification event to occur, including, but not limited to, cell
lysis, biological molecule capture, biological molecule separation,
and cellular culture, purification, and/or analysis. In some
embodiments, all of, or a subset of the reactions chambers are
dedicated for sample modification. For example, one or more
reaction chambers contain reagents that cause a biological molecule
(e.g., nucleic acid, protein, lipid, etc.) or cell modification
event to occur, including, but not limited to, amplification,
ligation, cleavage, labeling, extension, degradation, association
with a ligand, oligomerization, transfection, transformation,
transgenesis, division, differentiation, and the like. In some
embodiments, all of, or a subset of the reaction chambers are
dedicated for sample analysis. For example, one or more reaction
chambers contain reagents or other components that permit detection
or other types of analysis of a biological molecule or cells of
interest. In some embodiments, the chambers contain reagents that
permit development of a color, fluorescent signal, luminescent
signal or other detectable characteristic. In some embodiments, the
chambers are configured to optimize signal detection by a signal
reader (e.g., color reader, fluorescence reader, luminescence
reader, the human eye, etc.). One or more of the chambers may be
used for multiple different tasks, including purification,
modification, analysis, and/or detection.
[0011] The present invention is not limited by the manner in which
the chambers are configured or separated from one another. The
chambers may each be the same size and shape as one another or may
be different sizes or shapes. A wide variety of configurations may
be used. In some embodiments, the chambers are wells and the
lipophilic barrier sits on top of or below the wells, such that any
material that is transferred from one chamber to another, must pass
through the lipophilic material by moving up or down, and over. In
some embodiments, the chambers are created by the existence of the
lipophilic material. For example, in some embodiments, a lipophilic
material is deposited along one or more points in a channel or
channels (e.g., in a glass, plastic, or ceramic tube), to create
barriers between zones in the channel or channels. The channel may
be any size, including small sizes such as capillary tubes or
microfluidic channels. In some embodiments, that chambers and
barriers are configured so that a sample or biological molecule of
interest must travel through a linear series of reaction chambers.
However, in other embodiments, a sample or biological molecule in a
first reaction chamber may optionally skip one or more other
chambers. In some embodiments, the chambers are housed in a device
that has a size or shape configured to fit existing laboratory
equipment (e.g., automated robotic arms, plate holders (e.g.,
96-well), thermocyclers, fluorescent detectors, etc.). In some
embodiments, channels are used to separate reaction chambers, where
all or a portion of the channel contains the lipophilic material.
For example, in some embodiments, the device is configured similar
to a 96-well or 384-well plate with channels connecting two more of
the wells. In some embodiments, a pathway between two chambers
contains air, water, or other fluids, where the sample passes
through the air, water, or other fluid before and/or after entering
or leaving the lipophilic material.
[0012] In some embodiments, reaction chambers are microwells or
microtubes containing hydrophilic solutions and the lipophilic
substance is placed on top of or below the solution in a subset of
the chambers or in a separate chamber.
[0013] In some embodiments, the device comprises a transport
mechanism that permits transfer of a desired material from one
reaction chamber to another through the lipophilic material. For
example, in some embodiments, a biological molecule of interest is
associated with a magnetic particle, such as a magnetic bead, in
one of the reaction chambers. The biological molecule of interest
is moved from one chamber to the other by application of a magnetic
field (e.g., from a magnet) that causes the magnetic particle to
travel from a first chamber, through the lipophilic barrier, to a
second chamber. In other embodiments, an electrical field is
created to move biological molecules or components associated with
the biological molecules (e.g., ligands, beads, charge tags, etc.),
using charge, from one reaction chamber to another. In some
embodiments, centrifugal force is used to move biological molecules
of interest from one chamber to another, through the lipophilic
barrier. In some embodiments, pressure from a vacuum or from
suction is used to move materials between chambers. The present
invention is not limited by the mechanism of transport.
[0014] In some embodiments, the device comprises a vapor barrier to
prevent or reduce the loss of liquid during handling or use. In
some embodiments, the device is composed of a plurality of thin
layers of material stacked on one another. For example, in some
embodiments, the layers comprise an aluminum foil layer sandwiched
between plastic layers.
[0015] In some embodiments, the devices of the invention are
provided as a system (e.g., kit) that includes one or more other
components that permit sample acquisition, sample handling, sample
disposal, data collection, data analysis, and data presentation.
These components may be separate devices or may be integrated into
a single multi-component device. These components may include, but
are not limited to, medical devices, environmental sample handling
devices, protein purification devices, nucleic acid purification
devices, computers, software, and the like. One or more components
of the system or device can be automated. In some embodiments, one
or more components of the system are configured to work without
automation. For example, in a non-automated system, a handheld
magnet is provided to move samples from one chamber to another, a
heat block or water bath is used to create the desired reactions
temperatures, a hand held fluorescence detector is used to detect
signal or a signal is observed by eye.
[0016] The systems and devices of the invention find use with a
wide variety of samples. For example, in some embodiments, a sample
is a biological or environmental sample. Biological samples may be
obtained from animals (including humans) and encompass fluids,
solids, tissues, and gases. Biological samples include blood
products, such as plasma, serum and the like, as well as
cerebrospinal fluid, sputum, bronchial washing, bronchial
aspirates, urine, lymph fluids, and various external secretions of
the respiratory, intestinal and genitourinary tracts, tears,
saliva, milk, white blood cells, myelomas, biological fluids such
as cell culture supernatants, tissue (fixed or not fixed), cell
(fixed or not fixed), and the like. Environmental samples include,
but are not limited to, environmental material such as surface
matter, soil, water, and industrial samples.
DESCRIPTION OF THE FIGURES
[0017] FIG. 1 shows a cartridge for sample purification and PCR in
accord with some embodiments of the present invention.
[0018] FIG. 2 shows a cartridge for sample purification of some
embodiments of the present invention.
[0019] FIG. 3 shows layers of a foil laminate used in constructing
cartridges of some embodiments of the present invention.
[0020] FIG. 4 shows a drawing of a foil laminate cartridge used in
some embodiments of the present invention.
[0021] FIG. 5 shows (a) the position of a permanent magnet with
respect to two immiscible fluids and (b) a surface plot of magnetic
force on a particle in the x and y directions.
[0022] FIG. 6 shows an experimental set up for estimation of
surface tension using the weight drop method.
[0023] FIG. 7 shows an illustration of the various stages of a
sandwich assay in a tube-based microfluidic system.
[0024] FIG. 8 shows a plot of FL1 height verses Log (Biotin
concentration).
[0025] FIG. 9 shows a plot of events recorded by the flow cytometer
verses forward scatter, side scatter and FL1 height.
[0026] FIG. 10 shows an illustration of the movement of
streptavidin coated magnetic particles from one capillary to
another followed by reaction with biotin.
[0027] FIG. 11a shows the signal of streptavidin coated particles
after moving through oil containing a fluorescent dye. FIG. 11b
shows the signal of streptavidin coated particles after moving
through oil containing a fluorescent dye followed by agitation of
the particles in PBS buffer.
[0028] FIG. 12 shows a schematic of a two-chamber cuvette used in
some embodiments of the present invention.
[0029] FIG. 13 shows a schematic of a two-chamber cuvette used in
some embodiments of the present invention.
[0030] FIG. 14 shows qRT-PCR for HIV-1 from plasma using an
immiscible phase filter (IPF) method: Standard curve of C.sub.t
values for 4 different RNA concentrations run in duplicate plotted
verses the log.sub.10 of the HIV-1 viral copy number.
[0031] FIG. 15 shows a Bland-Altman plot comparing the IPF and
manual method of purification: Solid black squares show difference
between the two methods, solid line (y=-0.00772) plots the mean
difference between the two methods and the dashes lines show the
mean +2 and -2 standard deviations (SD) of the mean.
[0032] FIG. 16 shows IPF quantification by qPCR of Chlamydia from
urine samples.
[0033] FIG. 17 shows IPF quantification by qPCR of gonorrhea from
urine samples.
[0034] FIG. 18 shows Bland-Altman plot comparing the IPF and manual
method of purification of Chlamydia.
[0035] FIG. 19 shows a Bland-Altman plot comparing the IPF and
manual method of purification of gonorrhea.
[0036] FIG. 20 shows IPF PCR for proviral DNA from 25 .mu.L WB.
[0037] FIG. 21 shows a Bland-Altman plot comparing the IPF and
manual method of purification.
DEFINITIONS
[0038] To facilitate an understanding of this disclosure, terms are
defined below:
[0039] As used herein, the term "lipophilic material" refers to any
substance which is substantially immiscible in water, alcohol, or
other hydrophilic or aqueous fluid. In some embodiments, lipophilic
materials of the present invention have a low solubility for
substances that interfere with a particular biological process such
as nucleic amplification or biomolecule detection. In some
embodiments, lipophilic materials of the invention have a low vapor
pressure. Lipophilic substances tend to interact within themselves
and with other substances through van der Waals forces. They have
little to no capacity to form hydrogen bonds. Lipophilic substances
typically have large o/w (oil/water) partition coefficients.
[0040] "Water insoluble" and "hydrophobic" materials are used
synonymously in this specification. The terms include polymers that
are practically insoluble in water and freely soluble in volatile
lipophilic solvents such as methylene chloride and non-volatile
hydrophilic solvents, particularly N-methyl pyrollidone (NMP).
[0041] "Water-miscible" or "hydrophilic" materials refer to an
organic liquid that can be diluted with at least an equal part of
water without separation.
[0042] A property of "water-immiscible" or "lipophilic" materials
is that they cannot be diluted with at least an equal part of water
without separation.
[0043] "Purified polypeptide" or "purified protein" or "purified
nucleic acid" means a polypeptide or nucleic acid of interest or
fragment thereof which is essentially free of, e.g., contains less
than about 50%, preferably less than about 70%, and more preferably
less than about 90%, cellular components with which the polypeptide
or polynucleocide of interest is naturally associated.
[0044] The term "isolated" means that the material is removed from
its original environment (e.g., the natural environment if it is
naturally occurring). For example, a naturally-occurring
polynucleotide or polypeptide present in a living animal is not
isolated, but the same polynucleotide or DNA or polypeptide, which
is separated from some or all of the coexisting materials in the
natural system, is isolated. Such polynucleotide could be part of a
vector and/or such polynucleotide or polypeptide could be part of a
composition, and still be isolated in that the vector or
composition is not part of its natural environment.
[0045] "Polypeptide" and "protein" are used interchangeably herein
and include all polypeptides as described below. The basic
structure of polypeptides is well known and has been described in
innumerable textbooks and other publications in the art. In this
context, the term is used herein to refer to any peptide or protein
comprising two or more amino acids joined to each other in a linear
chain by peptide bonds. As used herein, the term refers to both
short chains, which also commonly are referred to in the art as
peptides, oligopeptides and oligomers, for example, and to longer
chains, which generally are referred to in the art as proteins, of
which there are many types.
[0046] It will be appreciated that polypeptides often contain amino
acids other than the 20 amino acids commonly referred to as the 20
naturally occurring amino acids, and that many amino acids,
including the terminal amino acids, may be modified in a given
polypeptide, either by natural processes, such as processing and
other post-translational modifications, but also by chemical
modification techniques which are well known to the art. Even the
common modifications that occur naturally in polypeptides are too
numerous to list exhaustively here, but they are well described in
basic texts and in more detailed monographs, as well as in a
voluminous research literature, and they are well known to those of
skill in the art. Among the known modifications which may be
present in polypeptides of the present are, to name an illustrative
few, acetylation, acylation, ADP-ribosylation, amidation, covalent
attachment of flavin, covalent attachment of a heme moiety,
covalent attachment of a nucleotide or nucleotide derivative,
covalent attachment of a lipid of lipid derivative, covalent
attachment of phosphatidylinositol, cross-linking, cyclization,
disulfide bond formation, demethylation, formation of covalent
cross-links, formation of cystine, formation of pyroglutamate,
formylation, gamma-carboxylation, glycosylation, GPI anchor
formation, hydroxylation, iodination, methylation, myrisoylation,
oxidation, proteolytic processing, phosphorylation, prenylation,
racemization, selenoylation, sulfation, transfer-RNA mediated
addition of amino acids to proteins such as arginylation, and
ubiquitination.
[0047] Such modifications are well known to those of skill and have
been described in great detail in the scientific literature.
Several particularly common modifications, glycosylation, lipid
attachment, sulfation, gamma-carboxylation of glutamic acid
residues, hydroxylation and ADP-ribosylation, for instance, are
described in most basic texts, such as for instance
Proteins--Structure and Molecular Properties, 2.sup.nd Ed., T. E.
Creighton, W. H, Freeman and Company, New York (1993). Many
detailed reviews are available on this subject, such as, for
example, those provided by Wold, F., Posttranslational Protein
Modifications: Perspectives and Prospects, pg. 1-12 in
Posttranslational Covalent Modification of Proteins, B. C. Johnson,
Ed., Academic Press, New York (1983); Seifter et al., Analysis for
protein modifications and nonprotein cofactors, Meth. Enzymol. 182:
626-646 (1990) and Rattan et al., Protein synthesis:
Posttranslational Modifications and Aging, Ann N.Y. Acad. Sci. 663:
48-62(1992).
[0048] It will be appreciated, as is well known and as noted above,
that polypeptides are not always entirely linear. For instance,
polypeptides may be branched as a result of ubiquitination, and
they may be circular, with or without branching, generally as a
result of posttranslational events, including natural processing
events and events brought about by human manipulation which do not
occur naturally. Circular, branched, and branched circular
polypeptides may be synthesized by non-translational natural
process and by entirely synthetic methods as well.
[0049] Modifications can occur anywhere in a polypeptide, including
the peptide backbone, the amino acid side-chains and the amino or
carboxyl termini. In fact, blockage of the amino or carboxyl group
in a polypeptide, or both, by a covalent modification, is common in
naturally occurring and synthetic polypeptides. For instance, the
amino terminal residue of polypeptides made in E. coli, prior to
proteolytic processing, almost invariably will be
N-formylmethionine.
[0050] The modifications that occur in a polypeptide often will be
a function of how it is made. For polypeptides made by expressing a
cloned gene in a host, for instance, the nature and extent of the
modifications in large part will be determined by the host cell
posttranslational modification capacity and the modification
signals present in the polypeptide amino acid sequence. For
instance, as is well known, glycosylation often does not occur in
bacterial hosts such as E. coli. Accordingly, when glycosylation is
desired, a polypeptide should be expressed in a glycosylating host,
generally a eukaryotic cell. Insect cells often carry out the same
posttranslational glycosylations as mammalian cells, and, for this
reason, insect cell expression systems have been developed to
express efficiently mammalian proteins having native patterns of
glycosylation. Similar considerations apply to other
modifications.
[0051] It will be appreciated that the same type of modification
may be present in the same or varying degree at several sites in a
given polypeptide. Also, a given polypeptide may contain many types
of modifications.
[0052] In general, as used herein, the term polypeptide encompasses
all such modifications, particularly those that are present in
polypeptides synthesized by expressing a polynucleotide in a host
cell.
[0053] The term "mature" polypeptide refers to a polypeptide which
has undergone a complete, post-translational modification
appropriate for the subject polypeptide and the cell of origin.
[0054] A "fragment" of a specified polypeptide refers to an amino
acid sequence which comprises at least about 3-5 amino acids, more
preferably at least about 8-10 amino acids, and even more
preferably at least about 15-20 amino acids derived from the
specified polypeptide.
[0055] The term "immunologically identifiable with/as" refers to
the presence of epitope(s) and polypeptide(s) which also are
present in and are unique to the designated polypeptide(s).
Immunological identity may be determined by antibody binding and/or
competition in binding. The uniqueness of an epitope also can be
determined by computer searches of known data banks, such as
GenBank, for the polynucleotide sequence which encodes the epitope
and by amino acid sequence comparisons with other known
proteins.
[0056] As used herein, "epitope" means an antigenic determinant of
a polypeptide or protein. Conceivably, an epitope can comprise
three amino acids in a spatial conformation which is unique to the
epitope. Generally, an epitope consists of at least five such amino
acids and more usually, it consists of at least eight to ten amino
acids. Methods of examining spatial conformation are known in the
art and include, for example, x-ray crystallography and
two-dimensional nuclear magnetic resonance.
[0057] A "conformational epitope" is an epitope that is comprised
of a specific juxtaposition of amino acids in an immunologically
recognizable structure, such amino acids being present on the same
polypeptide in a contiguous or non-contiguous order or present on
different polypeptides.
[0058] A polypeptide is "immunologically reactive" with an antibody
when it binds to an antibody due to antibody recognition of a
specific epitope contained within the polypeptide. Immunological
reactivity may be determined by antibody binding, more
particularly, by the kinetics of antibody binding, and/or by
competition in binding using as competitor(s) a known
polypeptide(s) containing an epitope against which the antibody is
directed. The methods for determining whether a polypeptide is
immunologically reactive with an antibody are known in the art.
[0059] As used herein, the term "immunogenic polypeptide containing
an epitope of interest" means naturally occurring polypeptides of
interest or fragments thereof, as well as polypeptides prepared by
other means, for example, by chemical synthesis or the expression
of the polypeptide in a recombinant organism.
[0060] "Purified product" refers to a preparation of the product
which has been isolated from the cellular constituents with which
the product is normally associated and from other types of cells
which may be present in the sample of interest.
[0061] "Analyte," as used herein, is the substance to be detected
which may be present in the test sample, including, biological
molecules of interest, small molecules, pathogens, and the like.
The analyte can include a protein, a polypeptide, an amino acid, a
nucleotide target and the like. The analyte can be soluble in a
body fluid such as blood, blood plasma or serum, urine or the like.
The analyte can be in a tissue, either on a cell surface or within
a cell. The analyte can be on or in a cell dispersed in a body
fluid such as blood, urine, breast aspirate, or obtained as a
biopsy sample.
[0062] A "specific binding member," as used herein, is a member of
a specific binding pair. That is, two different molecules where one
of the molecules, through chemical or physical means, specifically
binds to the second molecule. Therefore, in addition to antigen and
antibody specific binding pairs of common immunoassays, other
specific binding pairs can include biotin and avidin, carbohydrates
and lectins, complementary nucleotide sequences, effector and
receptor molecules, cofactors and enzymes, enzyme inhibitors, and
enzymes and the like. Furthermore, specific binding pairs can
include members that are analogs of the original specific binding
members, for example, an analyte-analog. Immunoreactive specific
binding members include antigens, antigen fragments, antibodies and
antibody fragments, both monoclonal and polyclonal and complexes
thereof, including those formed by recombinant DNA molecules.
[0063] Specific binding members include "specific binding
molecules." A "specific binding molecule" intends any specific
binding member, particularly an immunoreactive specific binding
member. As such, the term "specific binding molecule" encompasses
antibody molecules (obtained from both polyclonal and monoclonal
preparations), as well as, the following: hybrid (chimeric)
antibody molecules (see, for example, Winter, et al., Nature 349:
293-299 (1991), and U.S. Pat. No. 4,816,567); F(ab').sub.2 and
F(ab) fragments; Fv molecules (non-covalent heterodimers, see, for
example, Inbar, et al., Proc. Natl. Acad. Sci. USA 69: 2659-2662
(1972), and Ehrlich, et al., Biochem. 19: 4091-4096 (1980)); single
chain Fv molecules (sFv) (see, for example, Huston, et al., Proc.
Natl. Acad. Sci. USA 85: 5879-5883 (1988)); humanized antibody
molecules (see, for example, Riechmann, et al., Nature 332: 323-327
(1988), Verhoeyan, et al., Science 239: 1534-1536 (1988), and UK
Patent Publication No. GB 2,276,169, published 21 Sep. 1994); and,
any functional fragments obtained from such molecules, wherein such
fragments retain immunological binding properties of the parent
antibody molecule.
[0064] The term "hapten," as used herein, refers to a partial
antigen or non-protein binding member which is capable of binding
to an antibody, but which is not capable of eliciting antibody
formation unless coupled to a carrier protein.
[0065] A "capture reagent," as used herein, refers to an unlabeled
specific binding member which is specific either for the analyte as
in a sandwich assay, for the indicator reagent or analyte as in a
competitive assay, or for an ancillary specific binding member,
which itself is specific for the analyte, as in an indirect assay.
The capture reagent can be directly or indirectly bound to a solid
phase material before the performance of the assay or during the
performance of the assay, thereby enabling the separation of
immobilized complexes from the test sample.
[0066] The "indicator reagent" comprises a "signal-generating
compound" ("label") which is capable of generating and generates a
measurable signal detectable by external means. In some
embodiments, the indicator reagent is conjugated ("attached") to a
specific binding member. In addition to being an antibody member of
a specific binding pair, the indicator reagent also can be a member
of any specific binding pair, including either hapten-anti-hapten
systems such as biotin or anti-biotin, avidin or biotin, a
carbohydrate or a lectin, a complementary nucleotide sequence, an
effector or a receptor molecule, an enzyme cofactor and an enzyme,
an enzyme inhibitor or an enzyme and the like. An immunoreactive
specific binding member can be an antibody, an antigen, or an
antibody/antigen complex that is capable of binding either to the
polypeptide of interest as in a sandwich assay, to the capture
reagent as in a competitive assay, or to the ancillary specific
binding member as in an indirect assay. When describing probes and
probe assays, the term "reporter molecule" may be used. A reporter
molecule comprises a signal generating compound as described
hereinabove conjugated to a specific binding member of a specific
binding pair, such as carbazole or adamantane.
[0067] The various "signal-generating compounds" (labels)
contemplated include chromagens, catalysts such as enzymes,
luminescent compounds such as fluorescein and rhodamine,
chemiluminescent compounds such as dioxetanes, acridiniums,
phenanthridiniums and luminol, radioactive elements and direct
visual labels. Examples of enzymes include alkaline phosphatase,
horseradish peroxidase, beta-galactosidase and the like. The
selection of a particular label is not critical, but it should be
capable of producing a signal either by itself or in conjunction
with one or more additional substances.
[0068] "Solid phases" ("solid supports") are known to those in the
art and include the walls of wells of a reaction tray, test tubes,
polystyrene beads, magnetic or non-magnetic beads, nitrocellulose
strips, membranes, microparticles such as latex particles, and
others. The "solid phase" is not critical and can be selected by
one skilled in the art. Thus, latex particles, microparticles,
magnetic or non-magnetic beads, membranes, plastic tubes, walls of
microtiter wells, glass or silicon chips, are all suitable
examples. It is contemplated and within the scope of the present
invention that the solid phase also can comprise any suitable
porous material.
[0069] As used herein, the terms "detect", "detecting", or
"detection" may describe either the general act of discovering or
discerning or the specific observation of a detectably labeled
composition.
[0070] The term "polynucleotide" refers to a polymer of ribonucleic
acid (RNA), deoxyribonucleic acid (DNA), modified RNA or DNA, or
RNA or DNA mimetics. This term, therefore, includes polynucleotides
composed of naturally-occurring nucleobases, sugars and covalent
internucleoside (backbone) linkages as well as polynucleotides
having non-naturally-occurring portions which function similarly.
Such modified or substituted polynucleotides are well-known in the
art and for the purposes of the present invention, are referred to
as "analogues."
[0071] As used herein, the term "nucleic acid molecule" refers to
any nucleic acid containing molecule, including but not limited to,
DNA or RNA. The term encompasses sequences that include any of the
known base analogs of DNA and RNA including, but not limited to,
4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine,
pseudoisocytosine, 5-(carboxyhydroxylmethyl) uracil,
5-fluorouracil, 5-bromouracil,
5-carboxymethylaminomethyl-2-thiouracil,
5-carboxymethylaminomethyluracil, dihydrouracil, inosine,
N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil,
1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,
2-methyladenine, 2-methylguanine, 3-methylcytosine,
5-methylcytosine, N6-methyladenine, 7-methylguanine,
5-methylaminomethyluracil, 5-methoxy-aminomethyl-2-thiouracil,
beta-D-mannosylqueosine, 5'-methoxycarbonylmethyluracil,
5-methoxyuracil, 2-methylthio-N6-isopentenyladenine,
uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid,
oxybutoxosine, pseudouracil, queosine, 2-thiocytosine,
5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,
N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid,
pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.
[0072] The term "gene" refers to a nucleic acid (e.g., DNA)
sequence that comprises coding sequences necessary for the
production of a polypeptide, precursor, or RNA (e.g., rRNA, tRNA).
The polypeptide can be encoded by a full length coding sequence or
by any portion of the coding sequence so long as the desired
activity or functional properties (e.g., enzymatic activity, ligand
binding, signal transduction, immunogenicity, etc.) of the
full-length or fragment are retained. The term also encompasses the
coding region of a structural gene and the sequences located
adjacent to the coding region on both the 5' and 3' ends for a
distance of about 1 kb or more on either end such that the gene
corresponds to the length of the full-length mRNA. Sequences
located 5' of the coding region and present on the mRNA are
referred to as 5' non-translated sequences. Sequences located 3' or
downstream of the coding region and present on the mRNA are
referred to as 3' non-translated sequences. The term "gene"
encompasses both cDNA and genomic forms of a gene. A genomic form
or clone of a gene contains the coding region interrupted with
non-coding sequences termed "introns" or "intervening regions" or
"intervening sequences." Introns are segments of a gene that are
transcribed into nuclear RNA (hnRNA); introns may contain
regulatory elements such as enhancers. Introns are removed or
"spliced out" from the nuclear or primary transcript; introns
therefore are absent in the messenger RNA (mRNA) transcript. The
mRNA functions during translation to specify the sequence or order
of amino acids in a nascent polypeptide.
[0073] The term "nucleic acid amplification reagents" includes
conventional reagents employed in amplification reactions and
includes, but is not limited to, one or more enzymes having
polymerase activity, enzyme cofactors (such as magnesium or
nicotinamide adenine dinucleotide (NAD)), salts, buffers,
deoxynucleotide triphosphates (dNTPs; for example, deoxyadenosine
triphosphate, deoxyguanosine triphosphate, deoxycytidine
triphosphate and deoxythymidine triphosphate) and other reagents
that modulate the activity of the polymerase enzyme or the
specificity of the primers.
[0074] As used herein, the terms "complementary" or
"complementarity" are used in reference to polynucleotides (i.e., a
sequence of nucleotides such as an oligonucleotide or a target
nucleic acid) related by the base-pairing rules. Complementarity
may be "partial," in which only some of the nucleic acids' bases
are matched according to the base pairing rules. Or, there may be
"complete" or "total" complementarity between the nucleic acids.
The degree of complementarity between nucleic acid strands has
significant effects on the efficiency and strength of hybridization
between nucleic acid strands. This is of particular importance in
amplification reactions, as well as detection methods which depend
upon binding between nucleic acids.
[0075] The term "homology" refers to a degree of identity. There
may be partial homology or complete homology. A partially identical
sequence is one that is less than 100% identical to another
sequence.
[0076] As used herein, the term "hybridization" is used in
reference to the pairing of complementary nucleic acids.
Hybridization and the strength of hybridization (i.e., the strength
of the association between the nucleic acids) is impacted by such
factors as the degree of complementary between the nucleic acids,
stringency of the conditions involved, the Tm of the formed hybrid,
and the G:C ratio within the nucleic acids.
[0077] As used herein, the term "Tm" is used in reference to the
"melting temperature." The melting temperature is the temperature
at which a population of double-stranded nucleic acid molecules
becomes half dissociated into single strands. The equation for
calculating the Tm of nucleic acids is well known in the art. As
indicated by standard references, a simple estimate of the Tm value
may be calculated by the equation: Tm=81.5+0.41(% G+C), when a
nucleic acid is in aqueous solution at 1 M NaCl (see e.g., Anderson
and Young, Quantitative Filter Hybridization, in Nucleic Acid
Hybridization (1985). Other references include more sophisticated
computations which take structural as well as sequence
characteristics into account for the calculation of Tm.
[0078] As used herein the term "stringency" is used in reference to
the conditions of temperature, ionic strength, and the presence of
other compounds, under which nucleic acid hybridizations are
conducted. With "high stringency" conditions, nucleic acid base
pairing will occur only between nucleic acid fragments that have a
high frequency of complementary base sequences. Thus, conditions of
"weak" or "low" stringency are often required when it is desired
that nucleic acids which are not completely complementary to one
another be hybridized or annealed together.
[0079] The term "wild-type" refers to a gene or gene product which
has the characteristics of that gene or gene product when isolated
from a naturally occurring source. A wild-type gene is that which
is most frequently observed in a population and is thus arbitrarily
designed the "normal" or "wild-type" form of the gene. In contrast,
the term "modified" or "mutant" refers to a gene or gene product
which displays modifications in sequence and or functional
properties (i.e., altered characteristics) when compared to the
wild-type gene or gene product. It is noted that
naturally-occurring mutants can be isolated; these are identified
by the fact that they have altered characteristics when compared to
the wild-type gene or gene product.
[0080] The term "oligonucleotide" as used herein is defined as a
molecule comprised of two or more deoxyribonucleotides or
ribonucleotides, preferably at least 5 nucleotides, more preferably
at least about 10-15 nucleotides and more preferably at least about
15 to 30 nucleotides, or longer. The exact size will depend on many
factors, which in turn depends on the ultimate function or use of
the oligonucleotide. The oligonucleotide may be generated in any
manner, including chemical synthesis, DNA replication, reverse
transcription, or a combination thereof.
[0081] Because mononucleotides are reacted to make oligonucleotides
in a manner such that the 5' phosphate of one mononucleotide
pentose ring is attached to the 3' oxygen of its neighbor in one
direction via a phosphodiester linkage, an end of an
oligonucleotide is referred to as the "5' end" if its 5' phosphate
is not linked to the 3' oxygen of a mononucleotide pentose ring and
as the "3' end" if its 3' oxygen is not linked to a 5' phosphate of
a subsequent mononucleotide pentose ring. As used herein, a nucleic
acid sequence, even if internal to a larger oligonucleotide, also
may be said to have 5' and 3' ends. A first region along a nucleic
acid strand is said to be upstream of another region if the 3' end
of the first region is before the 5' end of the second region when
moving along a strand of nucleic acid in a 5' to 3' direction.
[0082] When two different, non-overlapping oligonucleotides anneal
to different regions of the same linear complementary nucleic acid
sequence, and the 3' end of one oligonucleotide points towards the
5' end of the other, the former may be called the "upstream"
oligonucleotide and the latter the "downstream"
oligonucleotide.
[0083] The term "primer" refers to an oligonucleotide which is
capable of acting as a point of initiation of synthesis when placed
under conditions in which primer extension is initiated. An
oligonucleotide "primer" may occur naturally, as in a purified
restriction digest or may be produced synthetically.
DETAILED DESCRIPTION OF THE INVENTION
[0084] The present invention relates to systems, devices, and
methods for performing biological reactions. In particular, the
present invention relates to the use of lipophilic barriers in
sample separation, purification, modification, and analysis
processes.
[0085] The systems, devices, and methods of the invention may be
configured, if desired, as inexpensive and easy-to-use sample
purification and/or modification and/or analysis and/or detection
systems. For example, embodiments of the present invention,
described herein, provide an economical means for widespread
biological molecule detection, analysis, and characterization.
These systems, device, and methods find many uses. To illustrate
aspect and benefits of the invention, its application to nucleic
acid and protein analysis, particularly for monitoring HIV
infection and status, are provided below. The invention is not
limited to these illustrative embodiments. In some embodiments, the
systems, devices, and methods of the invention are utilized in
conjunction with existing, complex, expensive sample separation,
purification, modification, and analysis equipments. For example,
in some embodiments, the approaches of the present invention are
used for sample preparation (e.g., nucleic acid or polypeptide
purification) prior to modification and/or analysis using
traditional equipment (e.g., thermocyclers, mass spectrometers, NMR
devices, etc.).
[0086] There are 35 million adults and children living with
HIV/AIDS, 22 million of them in sub-Saharan Africa. The average
clinic in Africa treats about 400 patients and the problem of
transportation is leading to an increase in the number of clinics
rather than the growth of large central facilities. Therefore,
there is a need for more than 100,000 viral load measuring
machines. The major limitations of currently available viral load
assays include the cost of the required instruments, the complex
and time-consuming procedures leading to the need for highly
trained personnel, and the need for cold-chain shipment of
reagents.
[0087] The development of affordable and simple HIV viral load
assays is a critical step for improving the quality of AIDS patient
care in the developing world. This would require automating complex
diagnostic procedures that are normally performed in a centralized
laboratory into small point of care (POC) devices; this capability
could empower health-care workers and patients with important
health-related information in even the most remote settings. The
required HIV viral load assay should preferably deliver answers at
the point of care, but moving it from remote central laboratories
to district hospital labs closer to the patient will improve
outcomes. Such a device will perform separation, amplification, and
detection of HIV with a short turnaround time and at an affordable
cost. A short time is critical since it would reduce the number of
machines needed in a clinic and reduce the time spent by the
patient at the clinic, thereby reducing the actual cost.
[0088] Many challenges must be overcome when conducting HIV viral
load assays both in centralized laboratories and out in the field.
Large laboratories use automated or semi-automated robotic systems
for high-volume HIV viral load assays. However, sample processing
is typically the most troublesome part of these tests. Currently,
sample-processing procedures involve many steps, often requiring
centrifugation and extraction steps. Also, these methods often do
not adequately purify the target nucleic acid. They often leave
inhibitory or interfering substances in the reaction mixture that
can cause inhibition of the amplification reaction and result in
false-negative results. The manual nature of current
sample-processing techniques also can lead to specimen
cross-contamination, which can cause false-positive results.
[0089] Considerable effort has been made in trying to automate the
sample preparation process, since this would allow for the more
widespread use of PCR or other nucleic analysis techniques.
However, existing automated high-throughput systems perform
multiple extraction and purification steps, and still require
certain manual preparations, including sample and reagent loading,
and waste removal. Hence, highly trained technicians are required
to conduct the assay and maintain the instrument. The automated
systems are very expensive because they use complex robotic arms to
move solutions or magnetic particles and precision instruments to
pipette liquids. The cost of an automated system is often difficult
to justify for smaller laboratories, especially those in resource
limited settings. Cross-contamination is also a problem since they
employ amplification technologies. Clinical laboratories often use
separate rooms for reagent preparation, sample preparation,
amplification, and post-amplification analysis. For these reasons,
despite the automation, viral load testing is considered
high-complexity tests under the Clinical Laboratory Improvement
Amendments (CLIA). To date, no Nucleic Acid Test (NAT) system has
qualified for CLIA-waived status, largely because of the
difficulties in automating sample preparation and reagent
handling.
[0090] Performing field-use or near-patient NATs involves even more
challenges, especially since they will inevitably be conducted by
less-experienced users in non-laboratory environments. The
following systems have recently been developed for deployment of
NATs in the field.
[0091] The GeneXpert system by Cepheid (Sunnyvale, Calif.) is one
of the first PCR-based instruments that integrate sample
preparation, amplification, and detection. The disposable
single-test GeneXpert sample-preparation cartridge consists of four
functional components: the cap, the cartridge body, the valve body
assembly, and the micro volume PCR reaction tube. The cartridge
body is divided internally into a number of chambers of various
sizes and functions, some containing the lyophilized reagent beads,
and each with a port at the bottom for fluidic inflow and outflow.
The chambers are radially arranged around the syringe barrel in the
center. The valve body assembly, located below the cartridge body,
is the site of cell lysing and DNA purification, under software
control, a rotary valve on the instrument moves the valve body
assembly so that fluids can be aspirated from or dispensed into the
appropriate chamber for mixing, dilution, and washing, according to
the programmed assay protocol. The reaction tube, which projects
from the cartridge, receives the prepared sample and interfaces
with the PCR reactor for amplification and detection of the target
analyte. To perform a test on the GeneXpert system, the operator
opens the cartridge cap and loads the liquid sample into the sample
chamber. When the operator closes the cap, the cartridge is
permanently sealed throughout the testing procedure and biohazard
disposal, eliminating any risk of cross-contamination of samples.
Cells are lysed by agitating tiny glass beads in the valve body
assembly by ultrasound generated directly below the cartridge. The
extracted DNA flows into a micro fluidic channel containing
immobilized DNA probes that DNA as the cellular debris flows over.
The bound DNA is later released from its attachment site and washed
off for PCR amplification.
[0092] Another system developed by IQuum Inc (Allston, Mass.) is
the Liat Molecular Analyzer based on its proprietary lab-in-a-tube
(Liat) technology platform. The Liat tube uses a flexible tube as
the sample vessel and contains all assay reagents pre-packed in
tube segments. The unit-dose reagents and internal controls can be
held separately in a series of tube segments in the order they are
used for an assay by using peelable seals. The peelable seal is
formed by a thermal weld of the plastic tube. By applying pressure
to the tube segments adjacent to each seal, the seal can burst open
to release reagents. In the Liat analyzer, multiple
sample-processor modules are aligned with the Liar tube. Each
module consists of an actuator and a clamp, whose positions can be
controlled to manipulate a test sample within a tube. A retractable
magnet is attached to one of the modules for manipulating magnetic
beads. When a tube is loaded in the analyzer, the actuators and
clamps compress the tube sequentially to move the reagents and
controls from one segment to another. Similarly, by synchronizing
the motion of the actuators and clamps, various sample processes
can be conducted within a tube. Such processes include adjusting a
liquid's volume in a segment; releasing a reagent to the adjacent
segment; mixing reagents and samples; agitating and incubating a
reaction mixture at a given temperature; and washing and removing
waste from a segment. Waste is moved toward a waste chamber in the
cap while the purified sample moves further down the tube. In the
lowest chamber, the released DNA is amplified.
[0093] Other commercialized real-time PCR devices intended for
field use include the Ruggedized Advanced Pathogen Identification
Device by Idaho Technology Inc. (Salt Lake City), the Hand-Held
Advanced Nucleic Acid Analyzer by Lawrence Livermore National
Laboratory (Livermore, Calif.), and the Bio-Seeq detector by Smiths
Detection (Pine Brook, N.J.). However, these devices do not have
automated sample preparation and reagent-handling functions.
[0094] The systems mentioned above are a step in the right
direction. However, the GeneXpert is still moderately complex to
operate and has to be operated by a trained technician. Since it
requires the user to pipette liquid in the field, a precision
measuring instrument would be needed which further increases the
cost of the system. Although the Liar Molecular Analyzer does not
involve measuring precise liquid volumes in the field, it is
expensive because of the complex mechanical system needed to move
fluids accurately. The Liat tube is difficult to manufacture, which
makes quality control difficult. The tube is difficult to store and
has leakage problems.
[0095] The controlled movement and delivery of small quantities
of-molecules such as proteins and chemical reagents represents an
ongoing challenge in micro fluidics and is of critical importance
for developing POC devices such as the HIV viral load device. The
majority of micro fluidic systems rely on fluid motion to move
solutions of molecules from one location to another, and as a
result, these systems unnecessarily consume solvent and materials
and involve complex mechanical systems to control fluid flow.
Embodiments of the present invention provide an alternative
approach to address the problem in the use of magnetic micro
particles as carriers to move molecules from one reaction media to
the next and remove all fluid flow from the system. Such an
approach where magnetic particles are manipulated using magnetic
forces allows one to carry out complex chemical reaction such as
viral load testing is a closed cartridge at a low cost. Since the
driving force in the reaction is a magnetic field, the system can
be automated, allowing for the construction of a portable, reliable
instrument for viral load tests with no contamination problems.
While the current system is exemplified for sample purification of
HIV viral RNA, the platform can easily be extended to other nucleic
acid tests and immunoassays, as well as detection of other
biological molecules or non-biological molecule of interest.
[0096] Embodiments of the present invention provide devices used to
perform sample purification and analysis assays in a single
instrument. In one exemplary embodiment (See e.g., Example 1) it
involves the use of magnetic particles as a solid phase for capture
of RNA, subsequent purification and release of RNA to carry out
amplification and detection.
[0097] Conventional devices conduct assays by exchanging solutions
contacting the solid phase. The solid phase may be a micro titer
well, a micro particle, or packed column. Even when the solid phase
is paramagnetic particles (PMP), assays are typically processed by
magnetically capturing the micro particles and exchanging solutions
in a single container. Embodiments of the invention use multiple
chambers to hold the test sample and water-based or water-alcohol
mixture wash buffers and the buffer for carrying out analysis. The
water based solutions in the chambers are separated by a lipophilic
material (e.g., a wax or oil) which is immiscible with the
solutions. This is illustrated, in some embodiments, with a wax
material and wells. The wax in the different wells connects to each
other forming a wax channel (FIG. 1). The wax can be solidified for
storage and transport. During the assay, the wax is melted and the
PMP are dragged up into the wax and moved from one compartment to
the next by passing them through the wax. Magnetic fields are used
to generate the force required to move the PMP and pass them
through the interface between the water based solution and the wax.
The maximum force is used to move the particles across the
interface and a flexible top plate is used to get the magnet close
to the interface and reduce the strength of the magnet required to
generate the force.
[0098] Moving PMP instead of fluids eliminates the need for pumps
and aspirators in automated processors and the need of trained
technician to aliquot liquids. The use of wax eliminates the need
for valves between compartments in single-use test cartridges used
in point-of-care analyzers. It also reduces the amount of
inhibitors carried over from one chamber to the next by reducing
the amount of liquid being carried over from one well to the next.
Since the force used to move the particles is magnetic, the system
can be completely closed, significantly reducing the risk of
contamination, which is a major problem in a sensitive assay such
as PCR.
I. Devices
[0099] As described above, the present invention provides the
ability to produce and use low cost devices for sample preparation
and analysis. In some embodiments, the devices are single-use or
multiple use and disposable. In some embodiments, the devices
utilize a plastic (or other material) cartridge comprising a
plurality of sample processing (e.g., sample preparation and/or
analysis) wells. Each well comprises a reagent for sample
preparation or analysis. The nature of the reagents depends on the
particular sample and analysis methods to be employed. In some
embodiments, the cartridge is composed of any material that is
chemically inert and provides adequate mechanical strength. In some
embodiments, the cartridge is constructed using a foil laminate
that comprises an aluminum layer for vapor barrier purposes and
inert polymer layers in contact with reagents. In embodiments that
involve the purification and analysis of RNA (e.g., viral detection
or load assays), it is preferred that the cartridge be RNA and
RNAse free. Sterilization methods known in the art can be utilized
to sterilize cartridges prior to use.
[0100] The cartridges of embodiments of the present invention are
covered with a material that segregates the sample processing
chambers. In some embodiments, the material is any lipophilic
material that has phase change characteristics and is immiscible
with the reagents for sample preparation and analysis and
substances in the sample which can interfere with amplification and
detection. In some embodiments, the material is a wax. In some
embodiments, the wax is a liquid at room temperature. In other
embodiments, the wax is a solid at room temperature and a liquid at
a temperature suitable for reactions. In other embodiments, the
lipophilic material is an oil. The lipophilic material may be
selected as optimal for use with a particular molecule of interest
in terms of temperature use, size exclusion, stability, and the
like.
[0101] In some embodiments, the lipophilic material separates the
sample processing chambers. In other embodiments, the lipophilic
material is located in between chambers but does not form the
physical barrier between the chambers. In such embodiments, the
sample may pass through air or other reagents before or after
passing through the lipophilic material.
[0102] The present invention is not limited to a particular
lipophilic material. In some embodiments, liphophilic materials are
immiscible in water and alcohol, exhibit low solubility in water
(e.g., ppm), are chemically inert, have melting and boiling points
compatible with assay processing (for example, perfluorohexame has
a by of 56.degree. C.), have a specific gravity different from
water (e.g., float or sink in water), have a low coefficient of
expansion, and are stable at 50.degree. C. for long periods of time
(e.g., weeks, months, or years).
[0103] Commercially available lipophilic materials that find use in
embodiments of the invention include, but are not limited to,
Chill-Out 14 wax (MJ Research), paraffin waxes such as IGI 1070A,
microcrystalline waxes such as IGI Micosere 5788A, soy and palm
waxes such as IGI R2322A, candle waxes such as IGI 6036A, thermoset
waxes such as IGI Astorstat 75, hot melt adhesives, atactic
polypropylene and polyolefin compounds, petroleum waxes, and dental
waxes.
[0104] In other embodiments, natural waxes such as animal waxes
(e.g., beeswax, lanolin, or) tallow, vegetable waxes (e.g.,
carnauba, candelilla, and soy) or mineral waxes such as fossil or
earth (e.g., ceresin or montan) or petroleum (e.g., paraffin or
microcrystalline) waxes are utilized. In yet other embodiments,
synthetic (man-made) waxes such as ethylenic polymers (e.g.,
polyethylene or polyol ether-esters), chlorinated naphthalenes or
hydrocarbon type waxes (e.g. Fischer-Tropsch) are utilized.
[0105] In some embodiments, oils such as mineral oil, paraffin oil,
silicon oil, fluorosilicone, fluorocarbon oil (e.g., Fluorinert
FC-40 from 3M), perfluorocarbon fluids (e.g., Flutec.RTM. Fluids
from F2Chemicals), perfluorodecalin (e.g., P9900 from Aldrich,
Flutec PP6, FluoroMed APF-140HP), perfluoroperhydrophenanthrene
(e.g., FluoroMed APF-215M) or perfluorooctylbromide (e.g.,
FluoroMed APF-PFOB) are utilized.
[0106] Additional barrier materials include, but are not limited
to, 1,4-Dioxane, acetonitrile, ethyl acetate, tert-butanol,
cyclohexanone, methylene chloride, tert-Amyl alcohol, tert-Butyl
methyl ether, butyl acetate, hexanol, nitrobenzene, toluene,
octanol, octane, propylene carbonate, and tetramethvlene sulfone
(See e.g., Chin et al., Biotechnology and Bioengineering 44:140
(1994); herein incorporated by reference in its entirety).
[0107] In still further embodiments, ionic liquids (e.g.,
BMIM[PF6], BMIM[Tf2N] and OMA[Tf2N] where:
BMIM-bis(trifluoromethanesulfonyl)imide,
PF6=1-n-butyl-3-methylimidazolium hexafluorophosphate,
TfN2=bis(trifluoromethylsulfonyl)imide, and
OMA=methyltrioctylammonium) are utilized as barrier materials. In
yet other embodiments, 1-Butyl-3-methylimidazolium
tetrafluoroborate ECOENG.TM. 21M ,
1-Ethyl-3-hydroxymethylpyridinium ethylsulfate,
Butylmethylpyrrolidiniumbis(trifluoromethylsulfonyl)imide,
ECOENG.TM. 212, or ECOENG.TM. 1111P (all available from Solvent
Innovations) are utilized as barrier materials.
[0108] The reagents provided in the different compartments of the
device may be any reagent for performing sample preparation and
analysis. Examples include, but are not limited to, cell lysis
buffer, wash buffers, affinity reagents, elution buffers, and
reaction components for biological assays. The devices of the
present invention are suitable for the purification of a variety of
biological molecules including, but not limited to, nucleic acids
(e.g., RNA, genomic DNA, oligonucleotides and the like), proteins
(e.g., peptides, peptide fragments, oligomeric proteins, protein
complexes, membrane proteins, and the like), and antibodies. The
devices of the present invention are suitable for carrying out any
number of biological assays including, but not limited to,
amplification of RNA or DNA (e.g., PCR, TMA, NASBA), detection of
nucleic acids (e.g., hybridization assays), and immunoassays.
[0109] In some embodiments, the device includes a component to
transport sample from one compartment of the device to the next. In
some embodiments, samples are associated with magnetic beads and
the transport component is a magnet. In other embodiments, the
transport component generates electric current to transport sample.
In still further embodiments, centrifugal force is utilized to
transport sample and the transport component generates such force
(e.g., by movement of the device). In other embodiments, a fluid
with a specific gravity greater than water is used such that the
fluid moves without mechanical intervention.
[0110] In some embodiments, the device includes a detection
component to detect a labeled or otherwise presence biological
sample or assay product. Examples include, but are not limited to,
spectrophotometers, mass spectrometers, NMR, microscopy and the
like. In some embodiments, products are read directly from the
final compartment of the device (e.g., using a window for
spectroscopy). In other embodiments, products are removed from the
device (e.g., using an automated component of the device) for
detection.
[0111] Embodiments of the present invention further provide a
device comprising fluidic chamber of reactants (e.g., a vertical
column) separated by a "wall" of lipophilic material which prevents
the reactants from mixing but allows microparticles to cross (e.g.,
magnetic particles transported by a magnet).
[0112] In some embodiments, the device and its use are automated.
An automated system comprises a device for sample purification and
analysis, a transport component for moving sample through the
device, and any additional components necessary, sufficient or
useful for the automation of the process (e.g. pre-processing
reagents and sample transport or post analysis detection or further
analysis components). In some embodiments where magnetic transport
is utilized, the transport component comprises a magnet that moves
between chambers of the device. In other embodiments, the device
moves relative to a stationary magnet or other transport
device.
II. Methods
[0113] As described above, the present invention provides sample
preparation and analysis devices and methods of using the
devices.
A. Sample
[0114] Any sample suspected of containing the desired material for
purification and/or analysis may be tested according to the
disclosed methods. In some embodiments, the sample is biological
sample. Such a sample may be cells (e.g. cells suspected of being
infected with a virus), tissue (e.g., biopsy samples), blood,
urine, semen, or a fraction thereof (e.g., plasma, serum, urine
supernatant, urine cell pellet or prostate cells), which may be
obtained from a patient or other source of biological material,
e.g., autopsy sample or forensic material.
[0115] Prior to contacting the sample with the device or as a
component of the device or automated system, the sample may be
processed to isolate or enrich the sample for the desired
molecules. A variety of techniques that use standard laboratory
practices may be used for this purpose, such as, e.g.,
centrifugation, immunocapture, cell lysis, and nucleic acid target
capture.
[0116] In other embodiments, the methods of embodiments of the
present invention are utilized to purify and/or analyze intact
cells (e.g., prokaryotic or eukaryotic cells).
B. Purification Methods
[0117] In some embodiments, the devices of the present invention
are utilized in sample preparation and purification. Any suitable
methods for purification may be utilized, including but not limited
to, target capture, washes, precipitations and the like. In some
embodiments, sample purification is carried out entirely in the
device and does not require any additional purification steps.
Purification may occur in one or more reaction chambers. This
decreases the complexity of purification and reduces cost. One of
skill in the art recognizes that the particular purification method
is dependent on the nature of the target biological sample.
C. Modification/Analysis/Detection
[0118] The purified sample may be detected using any suitable
methods, including, but not limited to, those disclosed herein. The
description below provides exemplary techniques for biological
molecules such as nucleic acids and proteins. Other techniques may
be applied for biological molecules or non-biological molecules, as
desired or needed.
i. Nucleic Acid Detection
[0119] Examples of nucleic modification/analysis/detection methods
include, but are not limited to, nucleic acid sequencing, nucleic
acid hybridization, and nucleic acid amplification. Illustrative
non-limiting examples of nucleic acid sequencing techniques
include, but are not limited to, chain terminator (Sanger)
sequencing and dye terminator sequencing. Those of ordinary skill
in the art will recognize that because RNA is less stable in the
cell and more prone to nuclease attack experimentally RNA is
usually reverse transcribed to DNA before sequencing. Illustrative
non-limiting examples of nucleic acid hybridization techniques
include, but are not limited to, in situ hybridization (ISH),
microarray, and Southern or Northern blot. Nucleic acids may be
amplified prior to or simultaneous with detection.
[0120] Illustrative non-limiting examples of nucleic acid
amplification techniques include, but are not limited to,
polymerase chain reaction (PCR), reverse transcription polymerase
chain reaction (RT-PCR), transcription-mediated amplification
(TMA), ligase chain reaction (LCR), strand displacement
amplification (SDA), and nucleic acid sequence based amplification
(NASBA). Those of ordinary skill in the art will recognize that
certain amplification techniques (e.g., PCR) require that RNA be
reversed transcribed to DNA prior to amplification (e.g., RT-PCR),
whereas other amplification techniques directly amplify RNA (e.g.,
TMA and NASBA).
[0121] The polymerase chain reaction (U.S. Pat. Nos. 4,683,195,
4,683,202, 4,800,159 and 4,965,188, each of which is herein
incorporated by reference in its entirety), commonly referred to as
PCR, uses multiple cycles of denaturation, annealing of primer
pairs to opposite strands, and primer extension to exponentially
increase copy numbers of a target nucleic acid sequence. In a
variation called RT-PCR, reverse transcriptase (RT) is used to make
a complementary DNA (cDNA) from mRNA, and the cDNA is then
amplified by PCR to produce multiple copies of DNA. For other
various permutations of PCR see, e.g., U.S. Pat. Nos. 4,683,195,
4,683,202 and 4,800,159; Mullis et al., Meth. Enzymol. 155: 335
(1987); and, Murakawa et al., DNA 7: 287 (1988), each of which is
herein incorporated by reference in its entirety.
[0122] Transcription mediated amplification (U.S. Pat. Nos.
5,480,784 and 5,399,491, each of which is herein incorporated by
reference in its entirety), commonly referred to as TMA,
synthesizes multiple copies of a target nucleic acid sequence
autocatalytically under conditions of substantially constant
temperature, ionic strength, and pH in which multiple RNA copies of
the target sequence autocatalytically generate additional copies.
See, e.g., U.S. Pat. Nos. 5,399,491 and 5,824,518, each of which is
herein incorporated by reference in its entirety. In a variation
described in U.S. Publ. No. 20060046265 (herein incorporated by
reference in its entirety), TMA optionally incorporates the use of
blocking moieties, terminating moieties, and other modifying
moieties to improve TMA process sensitivity and accuracy.
[0123] The ligase chain reaction (Weiss, R., Science 254: 1292
(1991), herein incorporated by reference in its entirety), commonly
referred to as LCR, uses two sets of complementary DNA
oligonucleotides that hybridize to adjacent regions of the target
nucleic acid. The DNA oligonucleotides are covalently linked by a
DNA ligase in repeated cycles of thermal denaturation,
hybridization and ligation to produce a detectable double-stranded
ligated oligonucleotide product.
[0124] Strand displacement amplification (Walker, G. et al., Proc.
Natl. Acad. Sci. USA 89: 392-396 (1992); U.S. Pat. Nos. 5,270,184
and 5,455,166, each of which is herein incorporated by reference in
its entirety), commonly referred to as SDA, uses cycles of
annealing pairs of primer sequences to opposite strands of a target
sequence, primer extension in the presence of a dNTPaS to produce a
duplex hemiphosphorothioated primer extension product,
endonuclease-mediated nicking of a hemimodified restriction
endonuclease recognition site, and polymerase-mediated primer
extension from the 3' end of the nick to displace an existing
strand and produce a strand for the next round of primer annealing,
nicking and strand displacement, resulting in geometric
amplification of product. Thermophilic SDA (tSDA) uses thermophilic
endonucleases and polymerases at higher temperatures in essentially
the same method (EP Pat. No. 0 684 315).
[0125] Other amplification methods include, for example: nucleic
acid sequence based amplification (U.S. Pat. No. 5,130,238, herein
incorporated by reference in its entirety), commonly referred to as
NASBA; one that uses an RNA replicase to amplify the probe molecule
itself (Lizardi et al., BioTechnol. 6: 1197 (1988), herein
incorporated by reference in its entirety), commonly referred to as
Q.beta. replicase; a transcription based amplification method (Kwoh
et al., Proc. Natl. Acad. Sci. USA 86:1173 (1989)); and,
self-sustained sequence replication (Guatelli et al., Proc. Natl.
Acad. Sci. USA 87: 1874 (1990), each of which is herein
incorporated by reference in its entirety). For further discussion
of known amplification methods see Persing, David H., "In Vitro
Nucleic Acid Amplification Techniques" in Diagnostic Medical
Microbiology: Principles and Applications (Persing et al., Eds.),
pp. 51-87 (American Society for Microbiology, Washington, D.C.
(1993)).
[0126] Non-amplified or amplified target nucleic acids can be
detected by any conventional means. For example, target mRNA can be
detected by hybridization with a detectably labeled probe and
measurement of the resulting hybrids. Illustrative non-limiting
examples of detection methods are described below.
[0127] One illustrative detection method, the Hybridization
Protection Assay (HPA) involves hybridizing a chemiluminescent
oligonucleotide probe (e.g., an acridinium ester-labeled (AE)
probe) to the target sequence, selectively hydrolyzing the
chemiluminescent label present on unhybridized probe, and measuring
the chemiluminescence produced from the remaining probe in a
luminometer. See, e.g., U.S. Pat. No. 5,283,174 and Norman C.
Nelson et al., Nonisotopic Probing, Blotting, and Sequencing, ch.
17 (Larry J. Kricka ed., 2d ed. 1995, each of which is herein
incorporated by reference in its entirety).
[0128] Another illustrative detection method provides for
quantitative evaluation of the amplification process in real-time.
Evaluation of an amplification process in "real-time" involves
determining the amount of amplicon in the reaction mixture either
continuously or periodically during the amplification reaction, and
using the determined values to calculate the amount of target
sequence initially present in the sample. A variety of methods for
determining the amount of initial target sequence present in a
sample based on real-time amplification are well known in the art.
These include methods disclosed in U.S. Pat. Nos. 6,303,305 and
6,541,205, each of which is herein incorporated by reference in its
entirety. Another method for determining the quantity of target
sequence initially present in a sample, but which is not based on a
real-time amplification, is disclosed in U.S. Pat. No. 5,710,029,
herein incorporated by reference in its entirety.
[0129] Amplification products may be detected in real-time through
the use of various self-hybridizing probes, most of which have a
stem-loop structure. Such self-hybridizing probes are labeled so
that they emit differently detectable signals, depending on whether
the probes are in a self-hybridized state or an altered state
through hybridization to a target sequence. By way of non-limiting
example, "molecular torches" are a type of self-hybridizing probe
that includes distinct regions of self-complementarity (referred to
as "the target binding domain" and "the target closing domain")
which are connected by a joining region (e.g., non-nucleotide
linker) and which hybridize to each other under predetermined
hybridization assay conditions. In a preferred embodiment,
molecular torches contain single-stranded base regions in the
target binding domain that are from 1 to about 20 bases in length
and are accessible for hybridization to a target sequence present
in an amplification reaction under strand displacement conditions.
Under strand displacement conditions, hybridization of the two
complementary regions, which may be fully or partially
complementary, of the molecular torch is favored, except in the
presence of the target sequence, which will bind to the
single-stranded region present in the target binding domain and
displace all or a portion of the target closing domain. The target
binding domain and the target closing domain of a molecular torch
include a detectable label or a pair of interacting labels (e.g.,
luminescent/quencher) positioned so that a different signal is
produced when the molecular torch is self-hybridized than when the
molecular torch is hybridized to the target sequence, thereby
permitting detection of probe:target duplexes in a test sample in
the presence of unhybridized molecular torches. Molecular torches
and many types of interacting label pairs are known (e.g., U.S.
Pat. No. 6,534,274, herein incorporated by reference in its
entirety).
[0130] Another example of a detection probe having
self-complementarity is a "molecular beacon" (see U.S. Pat. Nos.
5,925,517 and 6,150,097, herein incorporated by reference in
entirety). Molecular beacons include nucleic acid molecules having
a target complementary sequence, an affinity pair (or nucleic acid
arms) holding the probe in a closed conformation in the absence of
a target sequence present in an amplification reaction, and a label
pair that interacts when the probe is in a closed conformation.
Hybridization of the target sequence and the target complementary
sequence separates the members of the affinity pair, thereby
shifting the probe to an open conformation. The shift to the open
conformation is detectable due to reduced interaction of the label
pair, which may be, for example, a fluorophore and a quencher
(e.g., DABCYL and EDANS).
[0131] Other self-hybridizing probes are well known to those of
ordinary skill in the art. By way of non-limiting example, probe
binding pairs having interacting labels (e.g., see U.S. Pat. No.
5,928,862, herein incorporated by reference in its entirety) may be
adapted for use in the compositions and methods disclosed herein.
Probe systems used to detect single nucleotide polymorphisms (SNPs)
might also be used. Additional detection systems include "molecular
switches," (e.g., see U.S. Publ. No. 20050042638, herein
incorporated by reference in its entirety). Other probes, such as
those comprising intercalating dyes and/or fluorochromes, are also
useful for detection of amplification products in the methods
disclosed herein (e.g., see U.S. Pat. No. 5,814,447, herein
incorporated by reference in its entirety).
[0132] In some embodiments, detection methods are qualitative
(e.g., presence or absence of a particular nucleic acid). In other
embodiments, they are quantitative (e.g., viral load).
ii. Protein Detection
[0133] Examples of protein detection methods include, but are not
limited to, enzyme assays, direct visualization, and immunoassays.
In some embodiments, immunoassays utilize antibodies to a purified
protein. Such antibodies may be polyclonal or monoclonal, chimeric,
humanized, single chain or Fab fragments, which may be labeled or
unlabeled, all of which may be produced by using well known
procedures and standard laboratory practices. See, e.g., Burns,
ed., Immunochemical Protocols, 3.sup.rd ed., Humana Press (2005);
Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring
Harbor Laboratory (1988); Kozbor et al., Immunology Today 4: 72
(1983); Kohler and Milstein, Nature 256: 495 (1975). In some
embodiments, commercially available antibodies are utilized.
D. Data Analysis
[0134] In some embodiments, following purification and detection, a
computer-based analysis program is used to translate the raw data
generated by the detection assay (e.g., the presence, absence, or
amount of a given target molecule) into data of predictive value
for a clinician or researcher. In some embodiments, the software
program is integrated into an automated device. In other
embodiments, it is remotely located. The clinician can access the
data using any suitable means. Thus, in some preferred embodiments,
the present invention provides the further benefit that the
clinician, who is not likely to be trained in genetics or molecular
biology, need not understand the raw data. The data is presented
directly to the clinician in its most useful form. The clinician is
then able to immediately utilize the information in order to
optimize the care of the subject.
[0135] Any method may be used that is capable of receiving,
processing, and transmitting the information to and from
laboratories conducting the assays, information provides, medical
personal, and subjects. For example, in some embodiments of the
present invention, a sample (e.g., a biopsy or a serum or urine
sample) is obtained from a subject and submitted to a service
(e.g., clinical lab at a medical facility, genomic profiling
business, etc.), located in any part of the world (e.g., in a
country different than the country where the subject resides or
where the information is ultimately used) to generate raw data.
Where the sample comprises a tissue or other biological sample, the
subject may visit a medical center to have the sample obtained and
sent to the profiling center, or subjects may collect the sample
themselves (e.g., a urine sample) and directly send it to a
profiling center. Where the sample comprises previously determined
biological information, the information may be directly sent to the
profiling service by the subject (e.g., an information card
containing the information may be scanned by a computer and the
data transmitted to a computer of the profiling center using an
electronic communication systems). Once received by the profiling
service, the sample is processed and a profile is produced (i.e.,
expression data), specific for the diagnostic or prognostic
information desired for the subject.
[0136] The profile data is then prepared in a format suitable for
interpretation by a treating clinician. For example, rather than
providing raw data, the prepared format may represent a diagnosis
or risk assessment (e.g., viral load levels) for the subject, along
with recommendations for particular treatment options. The data may
be displayed to the clinician by any suitable method. For example,
in some embodiments, the profiling service generates a report that
can be printed for the clinician (e.g., at the point of care) or
displayed to the clinician on a computer monitor.
[0137] In some embodiments, the information is first analyzed at
the point of care or at a regional facility. The raw data is then
sent to a central processing facility for further analysis and/or
to convert the raw data to information useful for a clinician or
patient. The central processing facility provides the advantage of
privacy (all data is stored in a central facility with uniform
security protocols), speed, and uniformity of data analysis. The
central processing facility can then control the fate of the data
following treatment of the subject. For example, using an
electronic communication system, the central facility can provide
data to the clinician, the subject, or researchers.
[0138] In some embodiments, the subject is able to directly access
the data using the electronic communication system. The subject may
chose further intervention or counseling based on the results. In
some embodiments, the data is used for research use. For example,
the data may be used to further optimize the inclusion or
elimination of markers as useful indicators of a particular
condition or stage of disease.
E. Compositions & Kits
[0139] In some embodiments, systems and/or devices of the present
invention are shipped containing all components necessary to
perform purification and analysis (e.g., pre-loaded into the
device). In other embodiments, additional reaction components are
supplied in separate vessels packaged together into a kit.
[0140] Any of these compositions, alone or in combination with
other compositions disclosed herein or well known in the art, may
be provided in the form of a kit. Kits may further comprise
appropriate controls and/or detection reagents. Any one or more
reagents that find use in any of the methods described herein may
be provided in the kit.
EXPERIMENTAL
[0141] The following examples are provided to demonstrate and
illustrate certain preferred embodiments and aspects of the
compositions and methods disclosed herein, but are not to be
construed as limiting the scope of the claimed invention.
EXAMPLE 1
[0142] This example described moving paramagnetic micro particles
using magnetic forces to capture RNA, subsequent purification, and
release of RNA for amplification and detection. It also shows the
use of liquid wax, as an exemplary lipophilic material, as a valve
between the various chambers allowing for the movement of
paramagnetic micro particles while forming a barrier between the
various wash buffer.
(a) Fabrication of the Cartridge
[0143] Individual cartridges for the assay were prepared by
machining a sterile, clear round bottom polystyrene 96 well plate
(FIG. 1a). The wax channel was made using FDA compliant plain back
1/16'' polypropylene sheets. In order to fabricate the wax channel,
9495 LE acrylic adhesive transfer tape (3M, St. Paul, Minn.) meant
for low surface energy substrates was glued onto both sides of a
rectangular piece of plastic cut to the correct dimensions. A
rectangular channel was milled out of the plastic piece. The
milling process also cut the adhesive. In view of the poor thermal
conductivity and low melting point of polypropylene, special care
has to be taken while machining it. The burrs forming during
machining of the channel were removed using a razor blade. The top
plate is also made out of a polypropylene sheet. Tiny holes were
punched on the top plate to allow for the introduction of
fluids.
[0144] Polypropylene was used for the top plate and the channel
because of its excellent chemical resistance. The saturated
olefinic chains yield resistance to most oils and solvents, as well
as water-based chemicals, soaps, and moderate acids and bases. Few
other materials with the strength properties of polypropylene match
the chemical resistance of polypropylene. Also, polypropylene's
hard, high-gloss surface makes it desirable for environments where
there is concern for build-up that can interfere with flow
sterilization of the cartridge: it is preferred that a RNA free
environment is maintained throughout the test. While commercially
available plastic parts are radiated with gamma rays to sterilize
them, a protocol was developed to sterilize the plastic parts which
could be easily carried out in a laboratory setting. The wells to
be used for the test were sealed off using adhesive tape before
machining the plate. After the completion of machining, the
cartridge was washed using the following protocol: [0145] a. wash
twice with water [0146] b. wash twice with 100% ethyl alcohol
[0147] c. wash with RNaseZap.RTM. RNase Decontamination Solution
(Ambion, Austin, Tex.) [0148] d. wash twice with water
[0149] After the washing was complete, the cartridge was dried
overnight at 50.degree. C.
RNA purification Assay:
[0150] The assay was performed using 400 .mu.L, of plasma sample
containing 10.sup.6 copies/mL Armored RNA (Abbott Molecular, Des
Plaines, Ill.). Armored RNA is used instead of naked RNA as a test
sample because it is ribonuclease resistant and easily quantifiable
by copy number of RNA. It is also noninfectious, making it easy for
to handle.
[0151] In order to purify RNA from a plasma sample, the MagMAX
Viral RNA Isolation Kit (Ambion, Austin, Tex.) was employed. In
this method, the cells are disrupted using the classic method of
guanidium thiocyanate-based solution. This simultaneously releases
the viral RNA and deactivates the nucleases in the sample matrix.
The RNA then binds to the silica coated magnetic beads in the
presence of a chaotropic agent and alcohol. The beads are then
washed and eluted in aqueous low salt buffer.
[0152] Preparation of lysis/binding solution and bead mix: Carrier
RNA is added to the lysis/binding solution concentrate according to
Table 1 and mixed briefly. This is followed by the addition of 100%
isopropanol. In order to prepare the bead mix, 10 .mu.L of RNA
binding beads are mixed with 10 .mu.L of lysis enhancer for every
reaction. The beads are vortexed before aliquoting.
TABLE-US-00001 TABLE 1 Volume of reagents to be added to prepare
lysis buffer Reagent Amount Lysis/Binding soln. Concentrate 400
.mu.L Carrier RNA 2 .mu.L 100% isopropanol 400 .mu.L
Preparation of the Cartridge
[0153] 802 .mu.L of the lysis solution was added to a microfuge
tube along with 400 .mu.L of plasma sample containing armored RNA.
When adding sample, the pipette tips should be immerged slightly
into the solution to prevent aerosol formation leading to
contamination. The solution is vortex mixed gently for 30 seconds
and then 20 .mu.L of bead mix is added to the tube. The solution is
vortex mixed gently for 4 minutes on a vortex mixture to fully lyse
the viruses and bind RNA to the magnetic beads. The beads are
captured by leaving the microfuge tube on a magnetic stand. 600
.mu.L of the solution is removed and discarded away. The beads are
vortex mixed in the remaining 222 .mu.L of solution. This solution
is aliquoted into the first chamber of the cartridge. 150 .mu.L of
wash buffer 1 containing isopropanol is added to chamber two and
three respectively. 225 .mu.L of wash buffer 2 containing ethanol
is added to chamber four and five respectively. 50 .mu.L of elution
buffer is added to chamber 6.
[0154] The wax channel (FIG. 1-b) is now glued onto the cartridge
by peeling off the paper laminate of the adhesive transfer tape
attached to the wax channel and applying the wax channel to the
cartridge. This is followed by the adhesion of the top plate to the
wax channel following a similar process. Chill-Out Liquid Wax
(Bio-Rad Laboratories, Hercules, Calif.) is then pipetted into the
cartridge through the punched holes of the top plate till there is
no air gap remaining in the cartridge. FIG. 1 shows the image of
the completely filled cartridge with the different buffers and the
wax.
Sample Purification Protocol
[0155] (a) Purification in the cartridge. In the sample
purification process, a magnetic force is used to carry out the
various purification steps (FIG. 2), for example, magnetic
separation of the beads to accumulate them into a clump, movement
of the particles from the buffer to the wax, movement of the
particles in the wax, reintroduction of the particles into the next
buffer and agitation of the particles in the buffer (Sample C1 in
table 2). This magnetic force is produced by a permanent magnet.
The clump of particles was moved from lysis buffer in chamber 1 to
elution buffer in chamber 6 through the various wash buffers in
chambers 2-5. The particles were allowed to sit for 30 seconds in
each wash buffer, and for 10 minutes in the elution buffer. The
particles were moved magnetically in the buffers during these
times.
[0156] (b) Purification in a microfuge tube. The sample
purification was carried out using the Ambion MagMax kit in a
microfuge tube as well. In this case, the microfuge tube containing
the lysis buffer and the RNA binding PMPs was put on a magnetic
stand to capture the PMPs. Once capture in complete, the RNA
binding beads formed a pellet against the magnet in the magnetic
stand. The supernatant is aspirated out without disturbing the
beads. The tube was removed from the magnetic stand, and Wash
buffer 1 was added to it. The solution was agitated for 30 seconds.
A similar process of capture and aspiration was carried out. The
beads were washed twice with Wash Buffer 1 and twice with Wash
Buffer 2. In this study, two different combinations of wash buffer
volumes were used: (i) 300 .mu.L of wash buffer 1 and 450 .mu.L of
wash buffer 2 (sample C2 in table 2) (ii) 150 .mu.L of wash buffer
1 and 225 .mu.L of wash buffer 2 (sample C3 in table 2) After the 4
wash steps the beads were left open at room temperature to allow
the remaining alcohol to evaporate. The tubes were inspected for
any remaining alcohol since alcohol inhibits PCR. 50 .mu.L of
elution buffer was added and the sample agitated vigorously for 4
minutes. In each case, the particles are captured after elution and
12.5 .mu.L of the sample was used for RT-PCR using the Abbott Real
time Assay.
Results and Data Analysis
[0157] The table shown below shows the average Ct values for the
three Sample types Table 2 Samples and the Ct values for the
TABLE-US-00002 Sample Average Ct value Prototype cartridge +
reduced wash buffer 15.2 (C1) Ambion kit protocol in microfuge tube
16.7 Ambion kit in microfuge tube + reduced 20.1 wash buffer
(C3)
[0158] The data shows that there is a 2.8 fold (2 mean Ct
difference) improvement in RNA purification when the particles are
moved through wax. This occurs in spite of the reduction in the
wash buffer volume. Comparing the results with a similar volume of
wash buffer, there is a 30 fold improvement in RNA purification. In
the manual approach of sample purification, a significant amount of
solution would adhere to the particles, which cannot be aspirated
out. Therefore, while each wash step leads to the dilution of the
inhibitors which are carried from the lysis solution, it would take
a significant number of washes and wash buffer volume to dilute out
all the inhibitors completely. While using wax as a medium of
particles transport, the amount of liquid being carried is
significantly lower which leads to an improvement in Ct.
Effect of Alcohol on RT-PCR
[0159] Alcohol is a known inhibitor of PCR. Therefore, the Ambion
sample purification kit requires drying the particles in air before
eluding the RNA. In the new protocol described herein, the drying
step is completely removed. Again, this shows that the amount of
fluid being carried from one chamber to the next is minimal. It
also simplifies the sample purification process significantly
allowing for easy automation. The presence of smaller quantities of
inhibitors also allows for elution in smaller quantities of elution
buffer, which in turn speeds up the thermal cycling speed, thereby
reducing the time required to carry out the test.
EXAMPLE 2
Automation
[0160] An inexpensive automated sample purification system is
developed by moving magnetic particles instead of fluids. A
cartridge which can hold fluid through long periods of storage is
designed. This does away with any sort of pipetting in the field.
Optimization of the assay in this novel platform enables one to
improve the sample purification process and develop a better
understanding of the system. An automated system for carrying out
the purification allows for the measurement of viral load without
the need of highly trained lab technicians. The combination of a
closed cartridge and automated device would create a point of care
platform not only for HIV viral load, but for all kinds of nucleic
acid testing in a cheap, convenient manner with a reduced risk of
cross contamination.
[0161] Experiments to optimize the system include: [0162] a
Fabricate a cartridge using foil laminate to hold the chemicals for
storage and to carry out reactions. [0163] b Optimization of the
sample purification protocol in new cartridge. [0164] c Build a
robust automated system to remove man-power requirements a.
Fabricate a Prototype Cartridge to Carry out Sample
Purification
[0165] There are two parts to this fabrication: (a) Material used
to make the cartridge (b) design of the cartridge itself.
[0166] (a) Material. The material to be used to make the cartridge
preferably provides (a) a vapor barrier to hold the liquids through
long periods of storage without significant loss. (b) mechanical
strength; and (c) a chemically inert surface which does not stick
to the blood or particles present in the solution.
[0167] While polystyrene or polypropylene is the choice of material
for carrying out chemical assays because of their chemical
inertness, they do not provide the vapor barrier needed to store
the reagents for long periods of time. The vapor barrier of a
material is measured in terms of water vapor transmission rate
(WVTR) which is a measure of the passage of water vapour through a
substance.
[0168] WVTR=.DELTA.w/.DELTA.t A (g m.sup.-2s.sup.-1), Where
.DELTA.w/.DELTA.t is the amount of moisture loss per unit time of
transfer (g s.sup.-1) and A is the exposed area to moisture
transfer (m.sup.2)
TABLE-US-00003 TABLE 3 WVTR characteristics of some common plastics
Density Thickness Material (g/cm3) (mil) WVTR.sup.a WVTR.sup.b
Ultra Low 0.9015 10 0.3313 0.846 density poly Ethylene Low density
0.9188 2 0.17 0.4274 poly ethylene High density 0.9433 2.5 0.053
0.136 poly ethylene Poly propylene 0.8994 2.5 0.1015 0.2738
Rollprint foil 2.1011 3.5 0 0 laminate .sup.ag/mil/100 sq in/day at
30.degree. C. and 35% RH .sup.bg/mil/100 sq in/day at 40.degree. C.
and 35% RH
[0169] Table 3 shows table below shows the WVTR of some plastics
and of a foil laminate (RP#26-1244, Rollprint, Addison, Ill.). It
is evident that foil laminate provides excellent vapor barrier for
reagents during storage. Foil laminate has the added benefit of
being extremely inexpensive. The cost of a single cartridge made
out of foil laminate would not exceed a few cents. The various
layers of foil laminate to be used are shown in FIG. 3 below.
[0170] The foil laminate (Rollprint Packaging Products, Addison,
Ill.) contains a 2 mil Aluminum layer which is responsible for the
low WVTR making it ideal for the storage of reagents. The polyester
layer provides a chemically inert and hydrophobic surface preferred
for carrying out the assay. It also allows the foil to be heat
sealed to another piece of foil or plastic. The nylon outer surface
protects the aluminum surface from corrosion and also provides
mechanical strength to the foil laminate. The foil laminate lacks
rigidity. This can be overcome by packaging it in a rigid material.
It should be noted that while the foil laminate is virtually
impermeable to vapor, the seal between two layers of foil is not
and is responsible for some loss of vapor.
[0171] In other embodiments, a vacuum formed chamber made out of
polypropylene or polystyrene similar to a 96 well plate is used. In
some embodiments, in order to provide a vapor barrier, this would
be aluminized by vapor deposition.
[0172] (b) Shape and size of the cartridge. While the shape of the
chambers are governed by the various forces acting to move the
particles and the needs to simplify the automation, the size of the
chambers is governed by the chemistry associated with sample
purification. The prototype designing is done using a 3D Mechanical
CAD program, Solidworks (Solidworks Corporation, Concerd, Mass.).
An example of a cartridge based on the currently used volumes is
shown in FIG. 4. Changes in the chemistry or automation needs are
accommodated by changing the shape and size of the chambers
accordingly.
[0173] (c) Peelable layer and top plate: The top plate of the
cartridge is preferably transparent in order to make optical
readings during the thermal cycling. Not shown in the drawing is a
peelable foil laminate layer which sits between the top plate and
the foil chambers. This is similar to a printer ink cartridge. The
end of the peel comes out between the top plate and the wax layer.
This provides the vapor barrier optimum for long term storage.
Solid wax is present above and below the seal. The wax below allows
for the peel to be removed without risk of loss of reagent sticking
to the peel. Before the test, the peel is removed and the wax
melted. The top plate can be made flexible which allows us to
compress it to remove any air gap that forms because of the cavity
created by the removal of the seal. It also should be chemically
inert since it comes in contact with the particles when they are
dragged from one chamber to the next. The peelable seal is heat
sealed to the chambers. The distance between the chambers is
preferably 6 mm to allow for proper sealing, although other
dimensions may be used. This sealing process is carried out in
Rollprint Inc.
[0174] Fabrication. The fabrication of the aluminum foil cartridges
is done using a pinch press device that comprises a positive
hemispherical head which fits into a negative mold of the same
size. By pressing the foil between the positive head and the
negative mold, the foil is stretched to confirm with the shape of
the mold. While the yield strength and the tensile strength of the
laminate are not known, the standard industry practice is:
(Maximum area after making the chamber)<(2.times.area before
extension)
[0175] The wax channel, the solid support, for cartridge, the top
plate is all joined together using 3M adhesive transfer tape.
Several adhesives were tested before choosing this one because of
its excellent adhesion properties, especially to low surface energy
surfaces. The adhesive is laser cut to the correct size by GML
(Vadnais Heights, Minn.). Optimization of sample purification
protocol to improve assay performance:
[0176] The assay is performed using a silica coated PMP based
MagMax kit from Ambion. The kit protocol is optimized for best
performance in an assay format which involves sedimentation of the
beads and pipetting out of the fluid. It is not meant to be used
with the wax. In order to further understand the effects of the wax
on the sample purification and to optimize the sample purification
process, the following experiments are carried out:
[0177] 1. Carryover of water through the wax: Based on the initial
experiments, it was hypothesized that the carry-over of water or
buffer from one chamber to the next is reduced significantly on
moving the particles through the wax. This was based, in part, on
the results described above, which show the lack of inhibition due
to alcohol. In order to confirm this hypothesis, a known
concentration of a fluorescent dye, fluorescein is dissolved in
water. A known number of particles (as measured on a Luminex flow
cytometer) is added to this solution. Then, the particles are
magnetically moved through the wax into a known volume of
fluorescein free water. On measuring the concentration of
fluorescein in the starting sample and the final sample, one can
quantitatively estimate the volume of water being carried over from
one chamber to the next (V.sub.a).
[0178] The experiment has two controls which are used to compare
the results: (a) move the particles with a pick-pin from an
identical solution of fluorescein to water. This represents
currently available systems such as the Maxwell or Kingfisher. (b)
Collect the particles by putting the microfuge tube containing the
fluorescein solution and the particles on a magnetic stand and then
carefully pipetting out the solution. This is followed by the
addition of a fixed quantity of fluorescein free water.
[0179] An improvement in purification performance is quantified by
comparing the average volume of liquid carried across from one
chamber to the next. The variance is used to quantify the
variability in the purification process due to sample handling. The
experiment is repeated for different number of particles, different
initial volume of sample, and different fluorescein concentrations.
The volume of liquid being carried across is a fraction .PHI. of
the volume of the droplet (V) containing the particles which moved
into the wax.
(1-.PHI.)V=(4/3).pi.r.sup.3N
.PHI.V=V.sub.a
.PHI.=V.sub.a/(Va+4 .pi.r.sup.3N)
[0180] In the above equations, r is the radius of the particles and
N is the total number of particles. The volume of the droplet V is
dependant on N and therefore the volume of liquid .PHI. V is also
dependant of N. One would not expect .PHI. V to be dependent on the
initial volume of fluorescein solution, but rather on the
concentration of fluorescein. This experiment allows one to
determine the optimal wash steps and volume, or the volume of the
lysis buffer required.
[0181] 2. Selecting optimal wash step volume and number. The
protocol recommended by Ambion is optimized for a manual pipetting
procedure. It does not account for the presence of the wax.
Therefore, the protocol is optimized using wax. While all the
inhibitors present in blood plasma which inhibit PCR are not known
specifically, it is accepted that inhibition by most inhibitors is
concentration dependant. The results from the previous experiments
provide information about the effect of the wax on the removal of
fluids. Using that as a guide stick, the number of purification
steps is reduced. The reduction in the number of purification steps
reduces the complexity of the sample purification process, reduces
the cost of the test and the time required for the test. A
reduction in the inhibitor concentration allows for elution in a
smaller volume of elution buffer, leading to a further increase in
the RNA concentration and faster thermal cycling.
[0182] The sensitivity of a method is associated with the lower
limit of applicability of that method. In relation to chemicals,
the minimum detectable value often refers to the minimum detectable
net concentration or amount. [0183] Determination of the LOD [0184]
Calculation of the LOD differs between professional scientific
bodies and between different applications, but one definition of
the LOD is: [0185] LOD(mean of blanks)+K(sd)
[0186] Where mean of blanks=the mean value given to the blank
determinations associated with an assay; K=coverage factor
associated with a desired confidence level; and sd=standard
deviation of the blank determinations.
[0187] This calculation is unsuitable for estimating the LOD
associated with real-time quantitative PCR methods as the blank
controls typically have values equal to the highest cycle number
used in the PCR reaction. Additionally, if the assay has worked
correctly, the value of these blanks will all be the same and their
distribution truncated, thus precluding the calculation of a useful
standard deviation.
[0188] In order to overcome some of the difficulties encountered
with the traditional calculation of LOD described in the scientific
literature, one can define the LOD as the lowest copy number that
gives a detectable PCR amplification product at least 95% of the
time. This can also be interpreted as the lowest copy number that
can be distinguished from the background noise with a probability
of 95%. The current Rt-PCR assay using the Ambion kit for RNA
purification and Abbott Real time protocol for Rt-PCR has been
reported to have an LOD of 40 copies of RNA in 1,0 ml of plasma
sample. Preferred assays detect a minimum of 500 copies of RNA.
Thus, for every protocol, the sensitivity of the assay is measured
by creating a dilution curve of Ct verses copies of RNA. The
desired goal is to go from the lysis buffer to the elution buffer
without a single wash step. The purification assay is carried out
with different number of wash steps and wash volume.
3. Wax Melting Point
[0189] The wax that used in the experiments described in Example 1
has a melting point of 10C. Therefore, this wax is liquid at room
temperature. A wax (DyNAwax Reagent, Finland), which melts at 60C
or other higher melting temperature was is used in some
embodiments. This allows for storage of the wax as solid during
storage with subsequent melting just before the experiment, thereby
creating a phase change plug for the movement of particles. The
other advantage is that the presence of wax below the peelable seal
allows one to peel the foil without losing any fluid from the
chambers which might have stuck to the foil, However, this would
involve carrying out the experiment in a water bath or using a
peltier heater to heat the wax.
Automation of the Sample Purification Protocol:
[0190] An automated sample purification system is provided.
Automation has numerous benefits, namely :(a) the process does not
require a skilled worker, (b) provides for better understanding of
the system, (c) speeds up the assay development and testing
process, (d) reduces sample to sample variations by standardizing
the process.
[0191] (a) A first component is a stage to move magnets and
cartridge. In order to automate the process, a stage is built to
carry out the five processes, namely (a) Aggregation of the
particles in a fluid (b) dragging the fluid across the interface
(c) dragging the particle aggregate in the wax (d) dragging the
particle aggregate from the wax to the water (e) agitating the
particles in the fluid. In the manual mode of operation, the
cartridge was held steady while the magnet was displaced relative
to the cartridge. In order to create the complex motion
automatically, in some embodiments, the cartridge is moved with
respect to the magnets. Thus the magnets and/or the cartridge are
mounted on a moving stage. The decision on which to move is
dependent on ease of construction, cost and reliability of the
process. Stepper motors may be used to carry out the various
movements.
[0192] i) Aggregate the particles in the wash buffer. The design is
guided by a simple estimation of the forces involved. The motion of
a spherical magnetic particle of density P.sub.p, radius R.sub.p,
volume V.sub.p=(4.pi.Rp.sup.3)/3, and mass m.sub.p is governed by
several forces including, (a) the magnetic force due to all field
sources, (b) fluidic drag, (c) particle/fluid interactions
(perturbations to the flow field), (d) buoyancy, (e) gravity, (g)
thermal kinetics (Brownian motion), and (h) inter-particle effects
such as magnetic dipole interactions. In order to guide the design
parameters, the behavior of magnetic particles in low concentration
and slow flow regimes where the magnetic and viscous drag forces
dominate is modeled. Therefore, particle/fluid interactions and
interparticle effects are ignored. The gravitational force, which
while of second order might not be negligible depending on the
particle size, is included. According to classical al Newtonian
dynamics:
m.sub.p=dv.sub.p/dt=F.sub.m+F.sub.f+F.sub.g,
where, v.sub.p is the velocity of the particle, and F.sub.m F.sub.f
and F.sub.g are the magnetic, fluidic, interfacial and
gravitational forces, respectively. The magnetic force is obtained
using an "effective" dipole moment approach where the magnetized
particle is replaced by an "equivalent" point dipole with a moment
m.sub.p.eff (Furlani and Ng, 2006). The force on the dipole (and
hence on the particle) is given is given by:
[0193] F.sub.m=.mu..sub.f (m.sub.p.eff.gradient.)H.sub.a, where
.mu..sub.f is the permeability of the transport fluid, m.sub.p.eff
is the "effective" dipole moment of the particle, and H.sub.a is
the (externally) applied magnetic field intensity at the center of
the particle, where the equivalent point dipole is located. If the
particle is in free-space, m.sub.p.eff=V.sub.pM.sub.p and the above
equation reduces to the usual form F.sub.m=.mu..sub.0
(m.sub.p.gradient.)H.sub.a, where V.sub.p and M.sub.p are the
volume and magnetization of the particle, and
.mu..sub.0=4.pi..times.10.sup.-7 is the permeability of free space.
FIG. 5 shows the arrangement of a magnet above the fluidic chamber
and the surface plot of force on a particle in the x direction and
the y direction at a fixed distance from the magnet. The force
calculation requires a choice of particle size and material
properties of, Fe.sub.3O.sub.4 (magnetite), which make up the
particles. In the calculation shown, it was assumed that
Fe.sub.3O.sub.4 has a density p=5000 kg/m.sup.3, a saturation
magnetization of M=4.78.times.10.sup.5 A/m and the particle size is
0.5 micrometer. A program was written in Matlab to estimate the
magnetic force for a system consisting of one magnet or an array of
magnets. This enables one to calculate the magnetic force for
different magnets and arrangements of magnets. While the current
program can only estimate forces due to a linear array of magnets,
it is possible to generate a program to estimate a more complex
arrangement of magnets.
[0194] The fluidic force is predicted using the Stokes' law for the
drag on a sphere in uniform flow,
F.sub.f=-6.pi..eta.R.sub.p(v.sub.p-v.sub.f), where .eta. and
v.sub.f are the viscosity and the velocity of the fluid,
respectively. The gravitational force is given by
F.sub.g=-V.sub.p(.eta..sub.p-.eta..sub.f)gy, where .eta..sub.p and
.eta..sub.f are the densities of the particle and fluid,
respectively, and g=9.8 m/s.sup.2 is the acceleration due to
gravity. The gravitation force acts in the -y direction. The
gravitational force is often ignored when analyzing the
magnetophoretic motion of submicron particles, as it is usually
much weaker than the magnetic force.
[0195] Plugging the various forces into Newton's equation of
motion, it is possible to predict the approximate time it would
require for the particles to aggregate and even plot the particle
trajectories. These calculations are used to guide the design
parameters.
[0196] (ii) Measure the surface tension and drag the particles
across the interface. The strength of the magnet used in the
automated process is governed by the strength of the magnetic field
required to overcome the interfacial surface tension. While it is
difficult to move one particle across the interface, a particle
clump can be moved across the interface.
[0197] The interfacial force can be estimated as y2.pi.R.sub.p
where y is the interfacial tension between wax and buffer. The
interfacial force is measured using the weight drop method which
follows from Tate's law.
[0198] This is an accurate method of determining surface tension
and perhaps the most convenient laboratory one for measuring
surface tension of a liquid-air or liquid-liquid interface. As
illustrated in FIG. 6, the procedure is to form drops of the wax at
the end of a tube, allowing them to fall into a container
containing buffer. The weight of the drop is then used to determine
the surface tension. Tate's law gives a very simple expression for
W, the weight of a drop minus the displaced fluid: W=2.pi.ryf,
where is the radius of the tube from which the drop forms and f is
a function of the dimensionless ratio of r/V.sup.1/3, where V is
the drop volume. The system shown in FIG. 6 is used to measure the
surface tension between the wax and the various wash buffers. An
important precaution to be taken when employing this method is to
use a tip that has been ground smooth at the end and which is free
from any nicks. In the case of liquids that do not wet the tip, r
is the inner radius. The drops should also be fanned slowly
otherwise the drop weight will be high.
[0199] Having estimated the interfacial force, one can estimate the
magnetic force required to move the particles across the interface.
Therefore, the design criteria is: F.sub.m>F.sub.i, where and
F.sub.m F.sub.i are the magnetic and interfacial forces
respectively. This estimation neglects frictional force as well.
This estimation guided the choice of magnet. In order to reduce the
strength of the magnet required to move the particles from the
buffer to the wax, the magnet is moved as close to the interface as
possible. This is done with a flexible top plate. A flexible top
plate is also used so that it can be depressed to remove any air
gaps which may form when the foil laminate which lies between the
chambers and the top plate is peeled off.
[0200] iii) Drag the particle aggregate across the wax. The
equation of motion for dragging the particles through the wax is
similar to that of aggregation of the particles. However, in this
case, the motion is that of a droplet of fluid containing a
particle aggregate rather than that of a single particle. The net
frictional force is given by
[0201] F.sub.f=-6.pi..eta.R.sub.p(v.sub.p-v.sub.f), where R.sub.p
is the translational tensor which depends on the shape of the
droplet and the internal viscosity of the droplet. It is fairly
easy to drag the particle aggregate through the wax. During this
process, the particles come in contact with the top surface of the
cartridge. It is therefore preferred that the material used for the
top plate process is chemically inert and has a smooth surface
texture.
[0202] (iv) Drag the particle aggregate from the wax to the buffer.
Since the movement of particles from the wax to the wash buffer is
accompanied by a decrease in surface energy, this is a simple
process. A small magnetic force is sufficient to drag the particles
back into the water. Also, the gravimetric force aids the process
of the particle settlement.
[0203] (v) Verify the need for agitation: In the assay performed in
Example 1, the particles were agitated by moving a magnet around
the chamber. This was done since the sample purification process
involving manual pipetting required agitation of the particles in
the wash buffer by vortex mixing. While creating a variable
magnetic field is possible by moving magnets on a stage, it adds to
the cost of the assay. Thus, in some embodiments, agitation is not
used.
[0204] Software to control the movement of the stepper motors and
the cartridge. The USB port of a computer can be connected to a
stepper motor controller via a USB to RS232 converter. This allows
one to send commands to the motor using the hyper terminal. Any
serial communication software such as Docklight can be used to
effectively communicate with the stepper motor using RS232 command
sets.
[0205] Test the performance of the automated sample purification
system. In order to test the performance of the sample purification
system, the loss of particles is measured. This is compared to a
loss of performance in the manual form of the assay and the assay
with pipetting of fluids.
[0206] For this purpose, the particle concentration is measured
using the Luminex flow cytometer. Unlike ordinary flow cytometers,
the Luminex system has a positive flow control system which allows
one to count particles as well as measure the volume of solution
used, thereby enabling one to measure the concentration of the bead
solution. Loss of beads=Initial concentration of bead.times.Vol of
sample used-final concentration of beads x Vol of elution
buffer.
% loss of beads=(Loss of beads/Total initial number of
beads).times.100
[0207] The percentage loss of beads is measured at each stage of
the automation process to measure the performance of the system.
The aim is to reduce the percentage loss to less than what is
observed in a manual process. The mean % loss of beads and the
variance of % loss of beads are compared for the automated process
and the manual approach. An automated system is expected to have a
lower variance than a manual process.
EXAMPLE 3
Tubular Processor
[0208] This example describes a tubular processor for performing
biological reactions. The experimental setup for the diagnostic
assay is shown in FIG. 7. It consists of a 0.060'' internal
diameter tube (Small Parts Inc.) attached to a CAVRO 3000XL digital
pump. The digital pump is controlled through an RS232 interface.
The different wash buffers, analytes, solution containing magnetic
particles and silicone oil (Gelest Inc.) are pumped in from the
distal end of the tube.
[0209] The particles used for the experiment are carboxyl coated
smooth surface magnetic particles obtained from Spherotech Inc. The
SPHERO.sup.IM Smooth Surface Magnetic Particles have a thick layer
of polymer coating on the surface of the particles to fully
encapsulate the iron oxide coating. There is no exposed iron oxide
on the surface of the particles.
[0210] Cylindrical Neodymium magnets (Bunting Magnetics Co) are
moved along the length of the capillary. The magnets are located
around the capillary to mix the particles. Magnets of grade N3 5
and N40 were used for all experiments.
[0211] Teflon tubes were found to be better than glass tubes and
were used for all experiments. The particles stick to the glass
more than Teflon. It is hypothesized that Teflon, being more
hydrophobic than glass, repels the hydrophilic particles more than
glass which is hydrophilic because of the presence of the carboxyl
group on the particle surface. However, the particles do not stick
to Teflon because it is extremely hydrophobic.
[0212] Fluorescent reading is not taken in the tube for the
following experiments, although it is possible to attach an optical
system to the capillary system. After completion of the chemical
reaction, the particles are taken out of the tube and read in a
flow cytometer. All readings are standardized with respect to the
SPHERO Rainbow Calibration Particles. The SPHERO Rainbow
Calibration Particles contain a mixture of several similar size
particles with different fluorescence intensities. Every particle
contains a mixture of fluorophores that allows excitation at any
wavelength from 365 to 650 nm. This enables the calibration of all
channels in the flow cytometer with the same set of particles. The
fluorophores used are very stable but non-spectral matching to
commonly used fluorophores such as FITC, PE or PE-Cy5. Dilution of
a few drops of the particles flam the chopper bottle to 1 mL of a
diluent provides adequate particle concentration for flow cytometer
calibration. The diluted Rainbow Calibration Particles remain
stable following repeat freezing and thawing.
Strepatividin-Biotin Reaction in a Tubular Processor and a
Microfuge Tube
[0213] A tubular processor for use as a diagnostic device
preferably is able to carry out an assay without loss in
sensitivity. Moving the particles through oil could denature the
proteins bound to the particle or form a layer on the particle
making diffusion from the bulk solution to the particle surface
difficult.
[0214] A streptavidin-biotin system was utilized. The biotin-avidin
or biotin-streptavidin interaction has some unique characteristics
that make it beneficial as a general bridge system. Avidin,
streptavidin, and NeutrAvidin biotin-binding protein each bind four
biotins per protein molecule with high affinity and
selectivity.
[0215] Unlabeled Streptavidin coated SPHERO Smooth Surface Magnetic
Particles (1% w/v) with an average diameter of 3 .mu. were used for
the experiment. In each of the following experiments, 0.7*10.sup.6
magnetic particles were used. The particles were washed in
Phosphate Buffer Saline (PBS), magnetically separated and
resuspended in 60 .mu.L of PBS buffer containing 0.1% Nonidet P-40
detergent. Different concentrations of Alexa-488-Biotin were
dissolved in Na-Phosphate buffer containing 0.1% Nonidet P-40
[0216] The following solutions were injected into the capillary in
the sequence given, each separated by 60 .mu.L of silicone oil:
[0217] (a) 60 .mu.L of PBS buffer containing the magnetic particles
[0218] (b) 60 .mu.L wash buffer of PBS containing 0.1% Nonidet P-40
[0219] (c) 200 .mu.LNa-Phosphate buffer containing a known
concentration of Alexa-488-Biotin and 0.1% Nonidet P-40 [0220] (d)
60 .mu.L wash buffer of PBS containing 0.1% Nonidet P-40
[0221] The particles were first moved magnetically from
`solution-a` to the chamber containing the wash buffer
(solution-b). This cleans the particles of debris. They were then
moved to the chamber containing the Alexa-488-Biotin allowing the
Streptavidin coated particles to bind to Alexa-488Biotin
(solution-c). The particles were constantly mixed magnetically. The
reaction was allowed to continue for 90 minutes and then the
particles were moved to the next chamber (solution-d) to wash off
any debris which might have stuck to the particles. Moving the
particles from one chamber to the next through the silicone oil
involves the particles coming together into a clump so that they
can cross the oil-water barrier. Hence, each time the particles
move across from one chamber to the next, they are made to mix well
by moving the magnets. The particles are then collected and
fluorescence on the particle is measured in a flow cytometer.
[0222] The Alexa Fluor dyes used for the experiment are a series of
superior fluorescent dyes that span the near-UV, visible, and
near-IR spectra. These dyes, without exception, produce brighter
conjugates compared to fluorescein. The Alexa-488 absorbs light at
495 nm, emits at 519 nm and has an extinction coefficient of 71000.
The dye is water soluble and remains highly fluorescent over a
broad pH range.
[0223] An identical reaction was carried out in a microfuge tube.
0.7*10.sup.6 particles were washed in PBS, magnetically separated
and resuspended in 60 .mu.L of PBS buffer containing 0.1% Nonidet
P-40 detergent. The particles were then mixed with the following
solutions each time being magnetically separated before being
resuspended in the next solution. [0224] (a) 60 .mu.L of PBS buffer
containing the magnetic particles [0225] (b) 60 .mu.L wash buffer
of PBS containing 0.1% Nonidet P-40 [0226] (c) 200 .mu.L
Na-Phosphate buffer containing a known concentration of
Alexa-488-Biotin and 0.1% Nonidet P-40 [0227] (d) 60 .mu.L wash
buffer of PBS containing 0.1% Nonidet P-40
[0228] As was the case of the reaction in the capillary, the
Streptavidin coated magnetic particles were allowed to mix with
biotin containing buffer for 90 minutes. The particles were mixed
constantly during this time. Fluorescence readings were taken from
these particles and compared with the fluorescence readings of the
particles from the capillary system.
[0229] FIG. 8 shows the value of FL1 Height measured in a flow
cytometer at different concentrations of Biotin. The diamonds
represent the signal for a Streptavidin biotin reaction carried out
in the capillary system whereas the pink squares represent the
signal for a Streptavidin biotin reaction carried out in the
microfuge rube. All measurements were standardized by keeping the
third peak of the rainbow at a fixed value. As can be seen from the
plot, the particles are completely saturated until a Biotin
concentration of 10.sup.-10 M after which the signal starts
reducing. The amount of biotin which binds on to the Streptavidin
coated particles is similar irrespective of whether the reaction is
carried out in a capillary or a microfuge tube. The difference
between the two reactions is not statistically significant at all
measured concentrations of biotin. The graph shows that there is
some quenching in the fluorescent signal at high concentrations of
biotin. FIG. 8 shows 5 replicates for the Streptavidin-biotin
reaction in a tubular processor at a biotin concentration of
0.5*10.sup.-10 M. This represents the variability of the reaction
from one run to another.
[0230] The procedure followed for the experiment is the same as the
previous experiment described above. FIG. 9 consists of two
superimposed images measured for two sets of particles, namely:
[0231] (a) Streptavidin coated SPHERO Smooth Surface Magnetic
Particles reacting with 10.sup.-12M Biotin solution [0232] (b)
Streptavidin coated SPHERO Smooth Surface Magnetic Particles
reacting with deionized water
[0233] The forward scatter and the side scatter is the same for the
two sets of particles, as would be expected because of identical
size and surface roughness of the two sets of particles. The FL1
height, which is a measure of the amount of fluorescence emitted
off the particle surface and thereby a direct measure of the amount
of biotin bound to Streptavidin is different for the two sets of
particles. FIG. 9 shows that the median FL1 height (peak) when the
particles reacts with 10.sup.-12M Biotin is distinctly
distinguishable and greater than the median height when the
Streptavidin coated particles react with water. The sensitivity of
the device was found to be 10.sup.-12 M for biotin (more than 2 dB
above the blank).
Particle Transport Between Tubes
[0234] As shown in FIG. 10, one tube is inserted into another such
that the outer diameter of the thinner tube is almost equal to the
inner diameter of the larger tube. Streptavidin coated particles
are moved to the chamber containing PBS buffer. While doing so, it
also moves from one capillary to another. It is then moved to a
chamber containing PBS buffer containing 10.sup.-8M
Alexa-488-Biotin and 0.1% Nonidet-P40 (NP-40). Moving from one
chamber to another involves crossing regions of silicone oil. The
particles were allowed to react with Alexa-488-biotin for 90
minutes, after which the particles are taken out and their
fluorescence measured in a flow cytometer. The fluorescent readings
indicate that the reaction occur s in spite of moving from one
capillary to another.
[0235] In a portable diagnostic device, the reagents might be
potentially present in one tube while the sample to be measured may
be collected in another a separate tube or vessel suitable for
collection of sample. This experiment demonstrated the feasibility
of allowing the particles to react with the sample in a tube or
collection vessel and then moving them to another tube where the
remaining reagents are present, thereby allowing the proceeding
reactions to be carried out.
Effect of Silicone Oil
[0236] One of the factors that affects the diagnostic device is the
effect of the silicone oil on the particles. It was investigated if
the oil sticks to the particle during the movement of the particle
through the oil region. For this purpose, a fluorescent dye,
pyromethene 546, was dissolved in silicone oil. Pyromethene is an
oil soluble laser dye which fluoresces at 546nm. The particles were
made to move through a region of silicone oil containing
pyromethene 546. The particles were then taken out of the capillary
and the fluorescence signal was measured in a flow cytometer (FIG.
11a).
[0237] In another experiment, the particles were moved through
silicone oil containing pyromethene 546 and then mixed in PBS
buffer containing 0.1% Nonidet P40. A magnet was used to agitate
these particles. The particles were then taken out of the capillary
and the fluorescence signal measured in a flow cytometer as shown
in FIG. 11b.
[0238] The forward scatter value depicts the size of the particle
while the side scatter gives information about the surface property
of the particle. In FIG. 11a, the forward scatter plot shows a
broad distribution although the particles are about the same size.
This demonstrates that the oil is sticking to the particle or
droplets of oil of various sizes are formed. Upon agitating the
particles in PBS buffer after moving the particles through oil, the
particle size distribution shows two distinct peaks as expected,
namely the particles and the doublets of the particles (FIG. 11b).
The side scatter plot in FIG. 11a also shows two peaks suggesting
that there might be little droplets of oil formed as well. The FL1
median value of FIG. 11a is 73 which demonstrates that some of the
fluorescent dye has migrated with the particles. This can be washed
away by mixing the particles and therefore a lower fluorescence
value 38 is obtained in FIG. 11b.
[0239] EXAMPLE 4
Efficiency of Commercial Viral RNA Purification Using Liquid
Wax
[0240] This example demonstrates that a purification method that
transports RNA bound to paramagnetic particles through a liquid wax
medium is adaptable to commercially-available kits which employ
different types of particles and a variety of lysis, wash, and
elution buffers. The kits tested contained silica (Ambion), iron
oxide (AbbottlPromega) and cellulose (Cortex) magnetic particles.
In addition to differences in particle chemistry, these kits vary
in the composition of their respective lysis and elution buffers as
well as the intermediate wash buffers.
[0241] Viral particles spiked into normal plasma were purified
according to the kit manufacturers' instructions, including all of
the wash steps between lysis and elution, and determined the levels
of RNA by real time PCR. Spiked plasmas were then purified with the
wax phase method using only the lysis and elution buffers and
compared levels of RNA.
[0242] Comparison of RNA concentrations, expressed in Ct units,
showed that the efficiency of the liquid wax transfer purification
methodology is equivalent to that of procedures in
manufacturer-specified guidelines. Taken together, these results
indicate that the exclusion of the lysis buffer by liquid wax is an
appropriate replacement for the multiple manual washes typically
prescribed by RNA purification systems.
Wax-Bridge Cuvette
[0243] All experiments were performed in a two-chamber cuvette
shown in FIGS. 12 and 13, which were designed to facilitate moving
particles from the lysis buffer to the elution buffer. As shown in
FIG. 12, lysis buffer is added to the chamber on the left, and
elution buffer is added to the chamber on the right. Liquid wax is
then added which covers both buffer solutions and forms a bridge
between the two chambers. When a magnet is placed on the side wall
of the lysis chamber, particles are drawn to the wall forming a
pellet. As shown in FIG. 13, the magnet is then moved up dragging
the pellet along the wall through the lysis buffer into the oil
layer. The magnet is then moved laterally dragging the particles
through the oil bridge until the pellet is above the elution
chamber. Finally, the magnet is moved down dragging the particles
out of the oil into the elution buffer.
Manufacturers' Protocols
[0244] The Ambion MagMax Viral RNA Isolation Kit(Catalog No.
AM1929), Abbott/Promega M Sample Preparation System (Catalog No.
02K02-24), and Cortex Biochem MagaZorb.RTM. RNA Isolation
Kit(Catalog No. MB2001) were tested. Viral RNA samples were
processed with each manufacturer's reagents following the kit
protocols, which include multiple washing steps.
Liquid Wax Protocols
[0245] Ambion MagMax Viral RNA reagents:
Sample Lysis
[0246] 25 .mu.L of plasma containing 1.5.times.10.sup.6 cp/mL HIV-1
virions was added to 802 .mu.L of Lysis buffer (composition: 400
.mu.L manufacturer-supplied Lysis/Binding concentrate, 400 .mu.L
absolute isopropanol, 2 .mu.L manufacturer-supplied carrier RNA) in
1.5 mL screw-cap tubes and mixed by pipet. Lysis proceeds for up to
10 minutes at 50.degree. C., in the presence of 20 .mu.L
well-suspended magnetic particles (manufacturer-supplied;
composition: 10 .mu.L particles, 10 .mu.L Binding Enhancer).
Particles may be added following the intial lysis step or be
present during lysis; no discernable effect on purification
efficiency has been observed.
Cartridge Setup
[0247] Magnetic particles are sedimented on a magnetic rack and 600
.mu.L of supernatant liquid is discarded to permit loading into a
prepared cartridge. Up to 250 .mu.L, of the slurry containing lysis
buffer and RNA-bound particles is transferred to the `lysis`
chamber of the cartridge. 25 .mu.L of a manufacturer-supplied
Tris-EDTA elution buffer is loaded into the `elution` chamber of
the cartridge. Chill-Out Liquid Wax (Bio-Rad) is layered on top of
the fluid in both chambers such that a wax `bridge` is formed
across the top of the cartridge, typically requiring 800 .mu.L of
liquid wax. Cartridges for multiple samples may be prepared in
batch in this manner and arrayed on a fabricated rack.
Purification
[0248] RNA-bound beads are accumulated into a tight pellet by a
magnet. Cartridges are handled individually for the transfer of
particles from `lysis` to `elution` chambers. Magnetic particles
are transferred through the wax and into the elution buffer by
magnet in a steady manner such that the beads remain in a tight
pellet and carryover of lysis buffer is minimized. Once in the
elution buffer, the beads are mixed by manual manipulation of the
magnet.
[0249] Sample recovery
[0250] Liquid wax is aspirated from the cartridge such that a
minimal amount (1 mm at meniscus) remains over the `elution`
chamber without sample loss. The cartridge is set for 4 minutes at
-20 .degree. C. such that the liquid wax solidifies but the elution
buffer/bead slurry remains in liquid phase. The liquid wax plug can
be removed by pipet tip or pierced for extraction of elution
buffer. The elution buffer/bead slurry is transferred to a 1.5 mL
screw-cap tube and heated for up to 10 minutes at 70.degree. C. to
facilitate complete elution of viral RNA into the supernatant
buffer. Beads are sedimented on a magnetic rack and up to 50 .mu.L
of RNA in Tris-EDTA buffer is collected from each tube, ready to
use for qRT-PCR.
Abbott/Promega Reagents:
Sample Lysis
[0251] 25 .mu.L of plasma containing 1.5.times.10.sup.6 cp/mL HIV-1
virions was added to 600 .mu.L of Lysis buffer (supplemented with 2
.mu.L manufacturer-supplied carrier RNA) and 25 .mu.L iron-oxide
magnetic particles in 1.5 mL screw-cap tubes and mixed by pipet.
Lysis proceeds for up to 10 minutes at 50.degree. C.
Cartridge Setup
[0252] After lysis, magnetic particles were sedimented and 400
.mu.L of supernatant was discarded. 25 .mu.L of a high-salt elution
buffer is added to the `elution` chamber. Up to 250 .mu.L of the
slurry containing lysis buffer and RNA-bound particles is
transferred to the `lysis` chamber of the cartridge. Chill-Out
Liquid Wax (Bio-Rad) is layered on top of the fluid in both
chambers such that a wax `bridge` is formed across the top of the
cartridge, typically requiring 800 .mu.L of liquid wax. Cartridges
for multiple samples may be prepared in batch in this manner and
arrayed on a fabricated rack.
Purification and Sample Recovery
[0253] A procedure identical to that employed for the Ambion kit
was used.
Cortex Biochem Reagents:
Sample Lysis
[0254] 25 .mu.L of plasma containing 1.5.times.10.sup.6 cp/mL HIV-1
virions was treated with 20 .mu.L Protease K by gentle mixing in a
1.5 mL screw-cap tube. 2004 of manufacturer-supplied Lysis buffer
was added and the sample mixed by pulse-vortexing for 15 seconds,
followed by heating up to 15 minutes at 55.degree. C. 500 .mu.L of
manufacturer-supplied Binding buffer and 20 .mu.L of monodisperse
Maga Zorb Reagent was added to the sample and incubated 10 minutes
at room temperature (20.degree. C.) with occasional mixing by
inversion.
Cartridge Setup
[0255] Magnetic particles are sedimented on a magnetic rack and 500
.mu.L of supernatant liquid is discarded to permit loading into a
prepared cartridge. Up to 250 .mu.L of the slurry containing lysis
buffer and RNA-bound particles is transferred to the `lysis`
chamber of the cartridge. 25 .mu.L of a manufacturer-supplied
Tris-EDTA buffer was added to the `elution` chamber. Chill-Out
Liquid Wax (Bio-Rad) is layered on top of the fluid in both
chambers such that a wax `bridge` is formed across the top of the
cartridge, typically requiring 800 .mu.L of liquid wax. Cartridges
for multiple samples may be prepared in batch in this manner and
arrayed on a fabricated rack.
Purification and Sample Recovery
[0256] A procedure identical to that employed for the Ambion kit
was used, with the exception that the elution buffer/bead slurry
was heated to 70.degree. C. for 15 minutes to facilitate elution of
viral RNA.
Comparison of Procedures
[0257] The adaptability of various viral RNA purification
chemistries to the liquid wax purification method was evaluated by
qRT-PCR using reagents supplied with the Abbott m2000rt assay kit.
In each case, HIV-1 virion containing plasma was used as template
for qRT-PCR analysis and was complemented by appropriate positive
(pure HIV-1 transcript) and negative (mock plasma purification or
water) controls. All purification samples include carrier RNA as an
internal control and were performed in replicate. From each RNA
preparation, 5 .mu.L RNA was used for analysis, yielding 7,500
copies of HIV-1 RNA in each reaction. A qRT-PCR mixture for a
single sample is described in Table 4 below:
TABLE-US-00004 TABLE 4 Component Volume (.mu.L) m2000rt oligo.
pre-mix 8.75 Tth polymerase (Roche) 0.75 Manganese acetate (Roche)
2.5 Crowding reagents (5X) 5.0 Purified RNA 5.0 Nuclease-free
dH.sub.2O 3.0
[0258] Results of qRT-PCR Analysis
[0259] Ct values given by the qRT-PCR instrumentation are given in
Table 5 below:
TABLE-US-00005 TABLE 5 Multi-step Liquid Wax Wash Magnetic particle
type Mean Ct Mean Ct Silica (Ambion) 20.69 18.69 Iron oxide 21.86
19.00 (Abbott/Promega) Cellulose (Cortex 20.32 19.83 Biochem)
[0260] For a set number of HIV-1 template copies, there was little
variance observed in the reported Ct values from qRT-PCR analysis
between chemistries tested and purification method employed.
Negative amplification and mock purification controls in these
experiments gave no or negligible Ct values in these experiments.
The phase gate purification procedure is comparable in efficiency
to kit manufacturer protocols, demonstrating that the liquid wax
exclusion of lysis buffer and other PCR inhibitors is as effective
as multiple washing. Spectrophotometry of eluted RNA samples from
the AbbottlPromega samples shows no absorbance at 230 nm.
Guanidinium is present in high molar concentrations in this lysis
buffer and absorbs ultraviolet light at 230 nm; the absence of an
absorbance peak shows that the carryover of this contaminant is
low. That the observed Ct values are consistent across replicates,
largely invariant amongst purification chemistries and comparable
between purification methodologies demonstrates that good RNA
recovery has been achieved.
EXAMPLE 5
Isolation of CD4+ T-Cells
[0261] Fresh Peripheral Blood Mono-Nuclear Cells (PBMNC's) were
purchased from Allcells (Emeryville, Calif.). Dynabeads CD4
magnetic particles (4.5 um diameter), coated with anti-CD4 antibody
were purchased from Invitrogen (Carlsbad, Calif.).
[0262] 1.2 ml of PBMNC's were mixed with 50 .mu.l of the Dynabeads
CD4 magnetic particles. The capture reaction was allowed to go for
45 minutes at 4.degree. C. with gentle tilting and rotation. The
CD4+ve T-Cell positive isolation was compared using three
procedures.
[0263] a) Positive isolation using Dynabeads CD4 protocol: 200
.mu.l of the above stock was aliquoted into the Well 1 of the
research cartridge (shown in FIG. 12, labeled lysis buffer, and
FIG. 13). A magnet was placed on the side of the cartridge for 1
minute, causing the magnetic particles and captured cells to form a
pellet on the side. The supernatant was aspirated and discarded.
The pellet was washed 3 times by re-suspending in 200 .mu.l PBS and
separating using a magnet. After the final wash, 60 .mu.l of 0.2%
Triton X-100 was added to lyse the cells.
[0264] b) Positive extraction through Chill-Out Liquid Wax
(Bio-Rad, Hercules, Calif.). 200 .mu.l of the stock solution was
aliquoted into Well 1 of the research cartridge. 60 .mu.l of 0.2%
Triton X-100 lysis buffer was aliquoted into Well 2 of the research
cartridge (shown in FIG. 12, labeled elution buffer, and FIG. 13)
which was separated from Well 1 by Chill-Out Liquid Wax. A magnet
was placed on the side of the cartridge for 1 minute, drawing the
magnetic particles and captured cells onto the side of Well 1. The
pellet was then slowly moved through the wax into Well 2 by
dragging the magnet along the path shown in FIG. 13. The magnet was
used to agitate the particles in Well 2.
[0265] c) Positive extraction through canola oil
(Jewel-Osco/Supervalu, Eden Prairie, Minn.). 200 .mu.L of the stock
solution was aliquoted into Well 1 of the cartridge. 60 .mu.L of
0.2% Triton X-100 lysis buffer was aliquoted into the lysis chamber
which was separated from Well 2 by canola oil. A magnet was placed
on the side of the cartridge for 1 minute, drawing the magnetic
particles and captured cells onto the side of Well 1, The pellet
was then slowly moved with a magnet through the canola oil into
Well 2. The magnet was used to agitate the particles in Well 2.
[0266] The efficiency of the transfer through the lipophilc
barriers was determined by measuring the amount of cellular DNA in
an aliquot of the solution in Well 2 with a real-time PCR assay for
the .beta.2-microglobulin gene, In each of the experiments, the
particles were drawn to the side of Well 2 with a magnet; and 60
.mu.l of the lysed cell suspension was transferred into Eppendorf
tubes. 5 .mu.l of each sample was then obtained and used for RT-PCR
using the Phusion GC assay for .beta.2-microglobulin (New England
Biolabs, Ipswich, Mass.)
Results
[0267] Table 6 below shows the number of cycles required to reach
the threshold fluorescence intensity of the real time PCR
assay:
TABLE-US-00006 TABLE 6 Cell purification Ct value DynalBeads
protocol 27.59 Chill-Out Wax 27.14 Vegetable Oil 28.99
[0268] The results show that the Ct values obtained from the three
cell isolation procedures were comparable. Since the assay
quantified .beta.2-microglobulin, the results show that the genetic
material in the cells was preserved while being moved through the
wax and oil.
EXAMPLE 6
[0269] RNA purification from Plasma using Dextran PMPs:
[0270] In order to eliminate all wash steps for purifying nucleic
acids and to eliminate all contact between the processing system
and the sample, PMPs were transported between wells using an
externally applied magnetic field. The wells are connected with a
hydrophobic liquid through which PMPs are transported (FIG. 12).
The hydrophobic liquid acts as a barrier between the lysis chamber
and the elution chamber, preventing mixing of the two solutions.
Upon application of the magnetic force, the PMPs are moved through
the hydrophobic liquid, transporting NAs from the lysis chamber to
the elution chamber while the lysis and elution buffers remain
stationary. The hydrophobic liquid acts as an immiscible phase
filter (IPF), which reduces processing to only three steps: cell
lysis/NA binding, PMP transport, and NA elution. To demonstrate the
feasibility of incorporating IPF into a RNA purification protocol,
HIV-1 RNA was extracted from plasma as is done in measuring viral
load. Quantitative measurement of HIV-1 is important for monitoring
disease progression and evaluating antiretroviral drug therapy
outcome (Mylonakis, Paliou et al., Am. Fam. Phisician 63(3) 483
2001). Since viral load measurement is technically demanding due to
the relatively low viral copy number and abundance of PCR
inhibitors in samples derived from human blood (Dineva,
Mahilum-Tapay et al. Analyst 132: 1193-1199 2007), this assay
provides a good model system.
[0271] HIV-1 virus, acquired from Rush Virology Quality Assurance
Laboratory at 1.5.times.10.sup.6 copies/ml of plasma, was diluted
in seronegative plasma to obtain HIV-1 concentrations of 300, 60
and 12 copies/4 respectively. The Ambion MagMaxTM Total RNA
isolation kit (Applied Biosystem; Foster City, Calif.) manual
protocol was performed as per manufacturer's recommendations. For
purification with the IPF method, lysis and binding reagents
constituting of 200 .mu.L of Ambion Lysis/Binding solution
concentrate (Applied Biosystem; Foster City, Calif.), 200 .mu.L of
isopropyl alcohol, 1.mu.L of carrier RNA (Applied Biosystem; Foster
City, Calif.), 5 .mu.L of Ambion PMPs and 5 .mu.L of Binding
Enhancer (Applied Biosystem; Foster City, Calif.) were added to the
larger chamber of the cartridge and mixed. 50 .mu.L of plasma
containing HIV-1 virus was then added to it and mixed for 4 minutes
using the automated system. 50 .mu.L of elution buffer was
aliquoted into the smaller chamber of the IPF cartridge and the two
aqueous fluids were overlaid with Chillout.TM. liquid wax (Biorad
Laboratories; Hercules, Calif.) as shown in FIG. 12. An automated
system aggregated the PMPs for 2 minutes using the external magnet
and moved the aggregate from the lysis buffer to the elution
buffer. The elution buffer containing the PMPs was heated to
55.degree. C. for 10 minutes to elute the RNA. The PMPs were
aggregated and removed from the elution buffer. HIV-1 viral load
quantification was performed using the Abbott RealTime HIV-1
Amplification Reagent Kit (Huang, Salituro et al. 2007) (Abbott
Molecular, Des Plaines, Ill.) in 25 .mu.L reaction volumes with the
addition of 0.2 mg/mi bovine serum albumin (B8667, Sigma), 150 mM
trehalose (T9531; Sigma) and 0.2% Tween 20 (28320; Pierce Thermo
Fisher Scientific) and 5 .mu.L template. Amplification reactions
were performed in Cepheid SmartCycler II (Sunnyvale, CA).
[0272] The purified RNA was amplified using the Abbott RealTime
HIV-1 Amplification Kit. A PCR efficiency of E=102% was observed
(FIG. 14), indicating that the inhibitor carryover is minimal even
after eliminating the four wash steps and the alcohol evaporation
step required for the standard protocol. Comparing the IPF and the
standard protocol for RNA purification using the Ambion MagMax.TM.
Total RNA isolation kit showed that at 0.05 level of significance
(.alpha.=0.05), there was no statistical difference between the two
methods (p-value=0.967) (FIG. 15). Ten replicates each at several
low copy numbers were purified and it was found that 60 copies of
viral RNA could be detected in the PCR reaction with 100%
sensitivity. Because 50 .mu.L of plasma were used, this corresponds
to 600 copies per ml of blood with 100% sensitivity.
[0273] EXAMPLE 7
Purification of Chlamydia and Gonorrhea DNA from Urine
[0274] In order to eliminate all wash steps for purifying nucleic
acids and to eliminate all contact between the processing system
and the sample, PMPs were transported between wells using an
externally applied magnetic field. The wells are connected with a
hydrophobic liquid through which PMPs are transported (FIG. 12).
The hydrophobic liquid acts as a barrier between the lysis chamber
and the elution chamber, preventing mixing of the two solutions.
Upon application of the magnetic force, the PMPs are moved through
the hydrophobic liquid, transporting NAs from the lysis chamber to
the elution chamber while the lysis and elution buffers remain
stationary. The hydrophobic liquid acts as an immiscible phase
filter (IPF), which reduces processing to only three steps: cell
lysis/NA binding, PMP transport, and NA elution. To demonstrate the
feasibility of using the IPF method to extract NA from urine,
bacterial DNA was purified from Chlamydia trachomatis (CT) and
Neisseria gonorrhoeae (NG) for diagnosis of these sexually
transmitted diseases.
[0275] The urine samples were prepared by combining Chlamydia: ATCC
trachomatis serotype F in McCoy cell culture suspension and
lyophilized Neisseria gonorrhoeae resuspended in PBS containing 30%
glycerol with control urine (Fisher Scientific, PA). The manual
protocol was carried out using the Abbott RealTime CT/NG assay as
per the manufacturer's protocols. For purification with IPF method,
200 .mu.L of Ambion Lysis/Binding solution concentrate (Applied
Biosystem; Foster City, Calif.), 200 .mu.L of isopropyl alcohol, 1
.mu.L of carrier RNA (Applied Biosystem; Foster City, Calif.), 5
.mu.L of Ambion PMPs and 54 of Binding Enhancer (Applied Biosystem;
Foster City, Calif.) were mixed. 200 .mu.L of urine sample was then
added to it. The solution was heated to 55.degree. C. for 10
minutes and the two-step purification was carried out as with the
plasma samples. As described previously (Marshall et al., J. Clin.
Microbiol., 45:747-51, 2007), the purified DNA was amplified using
the Abbott RealTime CT/NG assay in a 50 .mu.L reaction volume.
Amplification reactions were performed in the Abbott Molecular
m2000rt instrument (Abbott Park, Ill.).
[0276] The PCR efficiency for the CT and NG assay over seven orders
of magnitude was 97.2% and 94.5% respectively (FIG. 16-17)
indicating that the inhibitor carryover is minimal. These
efficiencies were similar to those obtained from the manual
extraction method (87.9% and 87.9%, respectively) using the Abbott
RealTime CT/NG kit. The Bland-Altman plots of the CT and NG assays
show that there is no statistical difference between the standard
method using the Abbott DNA purification kit and the IPF method.
(FIG. 18-19). At a 0.05 level of significance (.alpha.=0.05), the
two were found to be identical (p-values of 0.42 and 0.70
respectively).
EXAMPLE 8
[0277] Purification of Genomic DNA from Whole Blood
[0278] In order to eliminate all wash steps for purifying nucleic
acids and to eliminate all contact between the processing system
and the sample, PMPs were transported between wells using an
externally applied magnetic field. The wells are connected with a
hydrophobic liquid through which PMPs are transported (FIG. 12).
The hydrophobic liquid acts as a barrier between the lysis chamber
and the elution chamber, preventing mixing of the two solutions.
Upon application of the magnetic force, the PMPs are moved through
the hydrophobic liquid, transporting NAs from the lysis chamber to
the elution chamber while the lysis and elution buffers remain
stationary. The hydrophobic liquid acts as an immiscible phase
filter (IPF), which reduces processing to only three steps: cell
lysis/NA binding, PMP transport, and NA elution.
[0279] Whole blood (WB) is a rich source of genomic DNA; however,
it is an extremely complex medium containing numerous PCR
inhibitors in high concentrations. To determine if the method could
process such samples, a qPCR assay was developed to detect proviral
HIV-1 DNA integrated into peripheral blood mononuclear cells.
Proviral DNA detection is used routinely to diagnose infants with
HIV-1 (Read and Committee on Pediatric AIDS Pediatrics 120(6):
el547-1562 2007). The Promega Magnesil gDNA purification kit which
consists of 10 steps (lysis, 7 washes, drying and elution) was
adapted for use with the IPF which involved 3 steps (lysis, PMP
transport through liquid wax, and elution).
[0280] Cultured 8E5 cells (Folks, Powell et al. J. Exp. Med.
164(1): 280-290 1986) (Rush Virology Quality Assurance Laboratory,
Chicago, IL) containing a single copy of the HIV-1 genome per cell
added to WB from a seronegative donor was used to simulate infant
blood for the proviral DNA assay. The cells were thawed, counted
using a hemoctyometer, serially diluted in phosphate buffer saline
(PBS) and added to WB from a seronegative donor at concentrations
of 8000 cells/.mu.l, 1600 cells/.mu.l, 320 cells/.mu.l and 64
cells/.mu.l. The Promega Magnesil gDNA purification protocol was
carried out at the manufacturer's recommendations. In the IPF
method, 254 blood was added to 60 .mu.L lysis buffer, agitated for
a minute and incubated for 4 minutes at room temperature. 44 .mu.L
of lysis buffer and 6 .mu.L, of PMPs was added, agitated for a
minute and incubated for 4 minutes. 15 .mu.L of lysis buffer and
200 .mu.L of alcohol wash buffer were added to the solution and the
IPF purification was carried out as before. The purified DNA was
amplified using the Abbott RealTime HIV-1 Amplification Reagent Kit
(Abbott Molecular, Des Plaines, Ill.) (Huang, Salituro et al. 2007)
in 25 .mu.l reaction volume. Amplification reactions were performed
in Cepheid SmartCycler II (Sunnyvale, Calif.).
[0281] Serial dilutions over 4 orders of magnitude yielded a
standard curve with a slope of -3.15 and PCR efficiency of 108%
(FIG. 20). The Bland-Altman plot of the proviral PCR assays showed
that there was no statistical difference between the standard
method using the Promega purification kit and the IPF method (FIG.
21). At a 0.05 level of significance (.alpha.=0.05), the two
methods were found to be identical (p-value=0.98).
[0282] All publications, patents, patent applications and sequences
identified by accession numbers mentioned in the above
specification are herein incorporated by reference in their
entirety. Although the invention has been described in connection
with specific embodiments, it should be understood that the
invention as claimed should not be unduly limited to such specific
embodiments. Modifications and variations of the described
compositions and methods of the invention that do not significantly
change the functional features of the compositions and methods
described herein are intended to be within the scope of the
following claims.
* * * * *